

STIC-Biotech/ChemLib

119643

From: Hamud, Fozia
Sent: Sunday, April 18, 2004 8:10 AM
To: STIC-Biotech/ChemLib
Subject: sequence search for 09/989725

Kindly search SEQ ID NO:417 of 09/989725 against commercial and interference data bases. Thanks.

Fozia Hamud
Patent Examiner
Art Unit 1647
Remsen: Room 4D64
Mail Box Remsen: 4C70
272-0884

RECEIVED
APR 19 2004
STIC

Searcher: _____
Phone: _____
Location: _____
Date Picked Up: *4/20/04*
Date Completed: *4/20/04*
Searcher Prep/Review: _____
Clerical: _____
Online time: _____

TYPE OF SEARCH: */*
NA Sequences: _____
AA Sequences: _____
Structures: _____
Bibliographic: _____
Litigation: _____
Full text: _____
Patent Family: _____
Other: _____

VENDOR/COST (where applic.)
STN: _____
DIALOG: _____
Questel/Orbit: _____
DRLink: _____
Lexis/Nexis: _____
Sequence Sys.: *04*
WWW/Internet: _____
Other (specify): _____



STIC Search Report

Biotech-Chem Library

STIC Database Tracking Number: 119643

TO: Fozia Hamud
Location: REM/4D64/4C70
Art Unit: 1647
Tuesday, April 20, 2004

Case Serial Number: 09/989725

From: Edward Hart
Location: Biotech-Chem Library
REM-1A55
Phone: 571-272-2512

edward.hart@uspto.gov

Search Notes

Examiner Hamud,

Here are the results of the search you requested.

Please feel free to contact me if you have any questions.

Edward Hart

601 CAACGTGCTGAACAAGGTAGAAATATGCACAGCAGCGCTGGAAGCTTCAAGTCCAAGACGA 660
661 GCGAAGTCTGCTTTGACCGCATGTTGCTCAGCTAAATGGGAATGAATCAAGGT 720
661 GCGAAGTCTGCTTTGACCGCATGTTGCTCAGCTAAATGGGAATGAATCAAGGT 720
721 GACTAGAAAGAAACAGGACAGCAACTGGAAGAACTGACTGGGTTTTCTGGGTTTCATT 780
721 GACTAGAAAGAAACAGGACAGCAACTGGAAGAACTGACTGGGTTTTCTGGGTTTCATT 780
781 TTAATACCTGTTGATTTTCAACCACTGTTGCTGGAAGATTCAAACTGGAGCAAAACT 840
781 TTAATACCTGTTGATTTTCAACCACTGTTGCTGGAAGATTCAAACTGGAGCAAAACT 840
841 TGCTTGATTTTTTTTCTGTTTAAAGTAAATATAGAGACATTTTAAAGACACACAGCTC 900
841 TGCTTGATTTTTTTTCTGTTTAAAGTAAATATAGAGACATTTTAAAGACACACAGCTC 900
901 AAAGTCAGCAATAGTCTTTTCTTCTTATTTGTCACCTTTTACTAATAAATAAATCTGCCT 960
901 AAAGTCAGCAATAGTCTTTTCTTCTTATTTGTCACCTTTTACTAATAAATAAATCTGCCT 960
961 GTAAATATCTTGAAGTCTTTTACCTGGAAACAGCACTCTCTTTTCCACCAATAGTTTTT 1020
961 GTAAATATCTTGAAGTCTTTTACCTGGAAACAGCACTCTCTTTTCCACCAATAGTTTTT 1020
1021 AACTTGACTTTCAAGATAATTTTCAAGGTTTTTGTGTTGTTTTGTTGTTGTT 1080
1021 AACTTGACTTTCAAGATAATTTTCAAGGTTTTTGTGTTGTTTTGTTGTTGTT 1080
1081 TTGGTGGGAGAGGAGGATCCCTGGGAAGTGTAAACACTTTTTTCAAGTCACTTTA 1140
1081 TTGGTGGGAGAGGAGGATCCCTGGGAAGTGTAAACACTTTTTTCAAGTCACTTTA 1140
1141 CTAAACAAACTTTTGTAAATAGACCTTACCTTCTATTTTCGAGTTTCATATATTTGTC 1200
1141 CTAAACAAACTTTTGTAAATAGACCTTACCTTCTATTTTCGAGTTTCATATATTTGTC 1200
1201 AGTGTAGCAGCTCATCAAGAGCTGACTTACTCATTTGCTTTGCTGCTGCTGCTGATT 1260
1201 AGTGTAGCAGCTCATCAAGAGCTGACTTACTCATTTGCTTTGCTGCTGCTGCTGATT 1260
1261 ATCTGGGTATCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 1320
1261 ATCTGGGTATCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 1320
1321 TTTTCAAAAAGAGAGATTTTCTTCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 1380
1321 TTTTCAAAAAGAGAGATTTTCTTCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 1380
1381 AAAGTGGCCATTTGCTAGTTTACTCTTAAAGACTAAACATAGTCTTGGTGGTGGTCTT 1440
1381 AAAGTGGCCATTTGCTAGTTTACTCTTAAAGACTAAACATAGTCTTGGTGGTGGTCTT 1440
1441 ACTCATCTCTAGTACCTTTTAGGCAAACTCTTAGGACTTGGACACTTGCATTAAGAA 1500
1441 ACTCATCTCTAGTACCTTTTAGGCAAACTCTTAGGACTTGGACACTTGCATTAAGAA 1500
1501 ATTTTATTTTAAACCAAGCTCCCTGGATTGATATATATACATTTGTCAGCATTTTC 1560
1501 ATTTTATTTTAAACCAAGCTCCCTGGATTGATATATATACATTTGTCAGCATTTTC 1560
1561 CGGTGCTGTGAGGAGCAGCTGTTTGGCTCCAAATATGTGAGCTTTGAACTAGGCTGG 1620
1561 CGGTGCTGTGAGGAGCAGCTGTTTGGCTCCAAATATGTGAGCTTTGAACTAGGCTGG 1620
1621 GGTGTGGGTGCTCTCTTGAAGGCTTAACTATTGATTAAGTGGCTTTTCTTCTCC 1680
1621 GGTGTGGGTGCTCTCTTGAAGGCTTAACTATTGATTAAGTGGCTTTTCTTCTCC 1680
1681 TATGTCCTCTTGGATGTAACAATAAATAATTTTGAACATCAA 1728
1681 TATGTCCTCTTGGATGTAACAATAAATAATTTTGAACATCAA 1728

RESULT 4

AAC91485

ID AAC91485 standard; cDNA; 1728 BP.

XX AAC91485;

XX 21-MAR-2001 (first entry)

XX Human PRO1375 cDNA.

XX Human; PRO; antiinflammatory; dermatological; antiarthritic;
XX antirheumatic; cardiac; antianaemic; immunosuppressive; antithyroid;
XX antidiabetic; nootropic; neuroprotective; hepatotropic; virucide;
XX antiallergic; antiasthmatic; immune related disorder;
XX hepatobiliary disease; autoimmune disease; allergy; ss.

OS Homo sapiens.

XX WO200073452-A2.

XX 07-DEC-2000.

XX 02-JUN-2000; 2000WO-US015264.

XX 02-JUN-1999; 99WO-US012252.

XX 20-JUL-1999; 99US-0144732P.

XX 20-JUL-1999; 99US-0144758P.

XX 28-JUL-1999; 99US-0146222P.

XX 01-SEP-1999; 99WO-US020111.

XX 15-SEP-1999; 99WO-US021090.

XX 15-SEP-1999; 99WO-US021547.

XX 29-OCT-1999; 99US-0162506P.

XX 30-NOV-1999; 99WO-US028313.

XX 01-DEC-1999; 99WO-US028634.

XX 02-DEC-1999; 99WO-US028551.

XX 02-DEC-1999; 99WO-US028565.

XX 09-DEC-1999; 99US-0170362P.

XX 20-DEC-1999; 99WO-US030911.

XX 05-JAN-2000; 2000WO-US000219.

XX 06-JAN-2000; 2000WO-US000376.

XX 11-FEB-2000; 2000WO-US003565.

XX 18-FEB-2000; 2000WO-US004341.

XX 18-FEB-2000; 2000WO-US004342.

XX 24-FEB-2000; 2000WO-US004414.

XX 24-FEB-2000; 2000WO-US004914.

XX 24-FEB-2000; 2000WO-US005004.

XX 01-MAR-2000; 2000WO-US005601.

XX 02-MAR-2000; 2000WO-US005841.

XX 03-MAR-2000; 2000US-0187202P.

XX 15-MAR-2000; 2000WO-US006884.

XX 20-MAR-2000; 2000WO-US007377.

XX 21-MAR-2000; 2000WO-US007532.

XX 30-MAR-2000; 2000WO-US008439.

XX 17-MAY-2000; 2000WO-US013705.

XX 22-MAY-2000; 2000WO-US014042.

XX (GBTH) GENENTECH INC.

XX Ashkenazi AJ, Baker KP, Chan B, Goddard A, Godowski RJ;

XX Gurney AU, Hebert C, Henzel W, Kabakoff RC, Shelton DL, Tumas D;

XX Watanabe CK, Wood WI;

XX WPI; 2001-025253/03.

XX P-PSDB; AAB50926.

XX Thirty three nucleic acids encoding PRO polypeptides which are useful in

XX the diagnosis and treatment of immune related disorders, e.g. systemic

XX lupus erythematosus, rheumatoid arthritis, osteoarthritis, thyroiditis

XX Claim 48; Fig 49; 218pp; English.

XX	The present sequence is one of thirty three nucleic acids encoding PRO			
CC	polypeptides. The PRO polypeptides, anti-PRO antibodies, agonists and			
CC	antagonists are useful for treating and diagnosing immune related			
CC	disorders such as systemic lupus erythematosus, rheumatoid arthritis,			
CC	osteoarthritis, juvenile chronic arthritis, spondyloarthropathies,			
CC	systemic sclerosis, idiopathic inflammatory myopathies, Sjogren's			
CC	syndrome, systemic vasculitis, sarcoidosis, autoimmune haemolytic			
CC	anaemia, autoimmune thrombocytopenia, thyroiditis, diabetes mellitus,			
CC	immune-mediated renal disease, demyelinating diseases of the central and			
CC	peripheral nervous systems (such as multiple sclerosis, idiopathic			
CC	demyelinating polyneuropathy or Guillain-Barre syndrome, and chronic			
CC	inflammatory demyelinating polyneuropathy), hepatobiliary diseases (such			
CC	as infectious, autoimmune chronic active hepatitis, primary biliary			
CC	cirrhosis, granulomatous hepatitis and sclerosing cholangitis),			
CC	inflammatory bowel disease, gluten-sensitive enteropathy and Whipple's			
CC	disease, autoimmune or immune-mediated skin diseases (such as bullous			
CC	skin diseases, erythema multiforme, contact dermatitis, psoriasis),			
CC	allergic diseases such as asthma, allergic rhinitis, atopic dermatitis,			
CC	food hypersensitivity and urticaria), immunological diseases of the lung			
CC	(such as eosinophilic pneumonias, idiopathic pulmonary fibrosis and			
CC	hypersensitivity pneumonitis), transplantation associated diseases			
CC	including graft rejection and graft-versus-host diseases			
XX				
SQ	Sequence 1728 BP; 438 A; 360 C; 390 G; 540 T; 0 U; 0 Other;			
	Query Match 100.0%; Score 1728; DB 5; Length 1728;			
	Best Local Similarity 100.0%; Pred. No. 0;			
	Matches 1728; Conservative 0; Mismatches 0; Indels 0; Gaps 0;			
QY	1	CAGCCGGGTCCCAAGCCTGTGCTGAGCCTGAGCCTGAGCCCGAGCCGGAGCC	60	
DB	1	CAGCCGGGTCCCAAGCCTGTGCTGAGCCTGAGCCTGAGCCCGAGCCGGAGCC	60	
QY	61	GGTGGGGGGGTCGGGGTGTGGACCGCTGGGGCCCGAGCGATGGCGACCCGTGGGG	120	
DB	61	GGTGGGGGGGTCGGGGTGTGGACCGCTGGGGCCCGAGCGATGGCGACCCGTGGGG	120	
QY	121	AGGCGCTTCCTGGGCTGGGCTCCTGCTCAGCCTGTGCTGGCGCTTCCTGGCTGCT	180	
DB	121	AGGCGCTTCCTGGGCTGGGCTCCTGCTCAGCCTGTGCTGGCGCTTCCTGGCTGCT	180	
QY	181	GCTGGGCGAGCTGTGAGACCGCGCCAGAAATTCGAGAGATGTCAGATGAATGTATCTG	240	
DB	181	GCTGGGCGAGCTGTGAGACCGCGCCAGAAATTCGAGAGATGTCAGATGAATGTATCTG	240	
QY	241	CCCTCCCTATAAGAAATTCCTGGGCATATTTATATAGAACATATCTCAGAAAGATTG	300	
DB	241	CCCTCCCTATAAGAAATTCCTGGGCATATTTATATAGAACATATCTCAGAAAGATTG	300	
QY	301	TGATTGCTTCATGTTGTGGAGCCCATGCTGTGGGGGGCTGTAGTAGAGCATCTG	360	
DB	301	TGATTGCTTCATGTTGTGGAGCCCATGCTGTGGGGGGCTGTAGTAGAGCATCTG	360	
QY	361	TCTACGCTGTGAATGCAATATGAGAAAGAGCTCTGTCAAACTCAAGGTTACCATAT	420	
DB	361	TCTACGCTGTGAATGCAATATGAGAAAGAGCTCTGTCAAACTCAAGGTTACCATAT	420	
QY	421	AATTTATCTCTCAATTTTGGGCTTCTACTTCTGTACATGGTATATCTTACTCTGGTTGA	480	
DB	421	AATTTATCTCTCAATTTTGGGCTTCTACTTCTGTACATGGTATATCTTACTCTGGTTGA	480	
QY	481	GCCCATACTGAAGAGCGGCTCTTTGGACATGCAAGTTGATACAGATGATGATAT	540	
DB	481	GCCCATACTGAAGAGCGGCTCTTTGGACATGCAAGTTGATACAGATGATGATAT	540	
QY	541	TGGGGATCACACGCTTTTGGCAATGCAACCATGTGCTAGCCCGCTCCCGCAGTCGAGC	600	
DB	541	TGGGGATCACACGCTTTTGGCAATGCAACCATGTGCTAGCCCGCTCCCGCAGTCGAGC	600	
QY	601	CAACGTGCTGAACAGAGTGAATATGCAACAGAGCGCTGGAAAGCTTCAAGTCCAAAGACA	660	
DB	601	CAACGTGCTGAACAGAGTGAATATGCAACAGAGCGCTGGAAAGCTTCAAGTCCAAAGACA	660	

QY	661	GCAGAAAGTCTGTCTTTGACCGGATGTTGTCTCAGCTAATTTGGGAATGAATCAAGGT	720	
DB	661	GCAGAAAGTCTGTCTTTGACCGGATGTTGTCTCAGCTAATTTGGGAATGAATCAAGGT	720	
QY	721	GACTAGAAAGAACAGCGACAGCAACTGGAAAGAACTGACTGGGTTTTCCTGGGTTTCATT	780	
DB	721	GACTAGAAAGAACAGCGACAGCAACTGGAAAGAACTGACTGGGTTTTCCTGGGTTTCATT	780	
QY	781	TTAATACCTTGTGATTTTCAACCAACTGTTGCTGGAAAGTTCAAAACTGGGAAGCAAAACT	840	
DB	781	TTAATACCTTGTGATTTTCAACCAACTGTTGCTGGAAAGTTCAAAACTGGGAAGCAAAACT	840	
QY	841	TGCTTGATTTTTTTTCTTGTTAAAGTAATTAATAGAGACATTTTAAAGACACACAGCTC	900	
DB	841	TGCTTGATTTTTTTTCTTGTTAAAGTAATTAATAGAGACATTTTAAAGACACACAGCTC	900	
QY	901	AAAGTCAGCCCAATAAGTCTTTTCTATTTGTGACTTTTACTAATAAAAATAAATCTGCCT	960	
DB	901	AAAGTCAGCCCAATAAGTCTTTTCTATTTGTGACTTTTACTAATAAAAATAAATCTGCCT	960	
QY	961	GTAAATATCTTGAAGTCTTTTACCTGGAAACAGACACTCTCTTTTCCACACATAGTTT	1020	
DB	961	GTAAATATCTTGAAGTCTTTTACCTGGAAACAGACACTCTCTTTTCCACACATAGTTT	1020	
QY	1021	AACCTGACTTTCAAGATAATTTTTCAGGGTTTTTGTGTTGTTGTTTGTGTTTGT	1080	
DB	1021	AACCTGACTTTCAAGATAATTTTTCAGGGTTTTTGTGTTGTTGTTTGTGTTTGT	1080	
QY	1081	TTGGTGGAGAGGGGAGGATGCTGGGAAAGTGGTTAAACAACTTTTTCAGTCACATTTA	1140	
DB	1081	TTGGTGGAGAGGGGAGGATGCTGGGAAAGTGGTTAAACAACTTTTTCAGTCACATTTA	1140	
QY	1141	CTAAACAACTTTTGTAAATAGACCTTACCTTCTATTTTCGAGTTTCATTATATTTTC	1200	
DB	1141	CTAAACAACTTTTGTAAATAGACCTTACCTTCTATTTTCGAGTTTCATTATATTTTC	1200	
QY	1201	AGTGTAGCCAGCTCTATCAAGAGCTGACTTACTATTTGACCTTTTTCGACTGCTGAT	1260	
DB	1201	AGTGTAGCCAGCTCTATCAAGAGCTGACTTACTATTTGACCTTTTTCGACTGCTGAT	1260	
QY	1261	ATCTGGGTATCTGCTGCTGCACCTTCTATGTAAGCGGATCTAAATGCCCTGGTGGCT	1320	
DB	1261	ATCTGGGTATCTGCTGCTGCACCTTCTATGTAAGCGGATCTAAATGCCCTGGTGGCT	1320	
QY	1321	TTTTCACAAAAGCAGATTTTCTTTCATGCTACTGTGATGTCTGATGCAATGCACTAGAAC	1380	
DB	1321	TTTTCACAAAAGCAGATTTTCTTTCATGCTACTGTGATGTCTGATGCAATGCACTAGAAC	1380	
QY	1381	AACTGGCCATTTGCTAGTTTACTCTTAAAGACTTAAACATAGTCTTGGTGTGCTGCTT	1440	
DB	1381	AACTGGCCATTTGCTAGTTTACTCTTAAAGACTTAAACATAGTCTTGGTGTGCTGCTT	1440	
QY	1441	ACTCATCTTCTAGTACCTTTAAGGACAAATPCTTAAGGACTTGGACACTTGGCAATAAGAA	1500	
DB	1441	ACTCATCTTCTAGTACCTTTAAGGACAAATPCTTAAGGACTTGGACACTTGGCAATAAGAA	1500	
QY	1501	ATTTTATTTTAAACCCAGCTCCCTGGGATGATATATATACACATTTGTCAGCATTTTC	1560	
DB	1501	ATTTTATTTTAAACCCAGCTCCCTGGGATGATATATATATACACATTTGTCAGCATTTTC	1560	
QY	1561	CGGTGCTGGTGGAGGCGAGCTGTTTGAGCTCCCAATATGTGAGCTTTGAAGTGGGCTGG	1620	
DB	1561	CGGTGCTGGTGGAGGCGAGCTGTTTGAGCTCCCAATATGTGAGCTTTGAAGTGGGCTGG	1620	
QY	1621	GGTTGTGGGTCCTTCTGAAAGGCTTAAACCATTTATTTGATTAACCTGGCTTTTCTTCC	1680	
DB	1621	GGTTGTGGGTCCTTCTGAAAGGCTTAAACCATTTATTTGATTAACCTGGCTTTTCTTCC	1680	
QY	1681	TATGTCCTCTTGGATGAACAAATAAATAATTTTGGAAACATCAA	1728	
DB	1681	TATGTCCTCTTGGATGAACAAATAAATAATTTTGGAAACATCAA	1728	

[illegible]

Qy	421	AATTTATCTCTCCAAATTTGGGCGCTTCTACCTTCGTCTGTA CATGGTATA TCTTACTCTGGTGGA	480
Dd	421	AATTTATCTCTCCAAATTTGGGCGCTTCTACCTTCGTCTGTA CATGGTATA TCTTACTCTGGTGGA	480
Qy	481	GCCCATACTGAAGAGGGCGCTCTTTTGACATGCACAGTTGATACAGAGTGGATGATGATAT	540
Dd	481	GCCCATACTGAAGAGGGCGCTCTTTTGACATGCACAGTTGATACAGAGTGGATGATGATAT	540
Qy	541	TGGGGATCACCAAGCCTTTTGCAAATGCACACGATGTGCTAGCCCGCTCCCGCAGTCGAGC	600
Dd	541	TGGGGATCACCAAGCCTTTTGCAAATGCACACGATGTGCTAGCCCGCTCCCGCAGTCGAGC	600
Qy	601	CACAGTCTGNAACAGGTAGAAATGACACAGCAGCGCTGGAGCTTCAAAGTCCAAGAGCA	660
Dd	601	CACAGTCTGNAACAGGTAGAAATGACACAGCAGCGCTGGAGCTTCAAAGTCCAAGAGCA	660
Qy	661	GCGBAAGTCTGTCTTTGACC GGCGATGTGCTCAGCTAATTGGGAATTTGAAATTTCAAGGT	720
Dd	661	GCGBAAGTCTGTCTTTGACC GGCGATGTGCTCAGCTAATTGGGAATTTGAAATTTCAAGGT	720
Qy	721	GACTAGAAAAGAACAGSAGACNACTGGAAAACTGACTGGGTTTTTGGCTGGGTTTCATT	780
Dd	721	GACTAGAAAAGAACAGSAGACNACTGGAAAACTGACTGGGTTTTTGGCTGGGTTTCATT	780
Qy	781	TTAATACCTTGTTCATTTCACCAACTGTGCTGGAAGATTCAAAATCTGGAAGCAAAAACT	840
Dd	781	TTAATACCTTGTTCATTTCACCAACTGTGCTGGAAGATTCAAAATCTGGAAGCAAAAACT	840
Qy	841	TGCTTGATTTTTTTTTCTTGTTAAGTAATAATAGACATATTTTAAAAAGCACACAGCTC	900
Dd	841	TGCTTGATTTTTTTTTCTTGTTAAGTAATAATAGACATATTTTAAAAAGCACACAGCTC	900
Qy	901	AAAGTCAGCCAA TAAGTCTTTTCTCTATTTGTGACCTTTTACTATAAAAAATAAATCTGCCCT	960
Dd	901	AAAGTCAGCCAA TAAGTCTTTTCTCTATTTGTGACCTTTTACTATAAAAAATAAATCTGCCCT	960
Qy	961	GTAATATCTTTGAAGTCTTTTACCTCGEAAACAAGCACTCTCTTTTTCACCACATAGTTTT	1020
Dd	961	GTAATATCTTTGAAGTCTTTTACCTCGEAAACAAGCACTCTCTTTTTCACCACATAGTTTT	1020
Qy	1021	AACCTTGACTTTCAAGATAATTTTTCAGGGTTTTTGTGCTGTTGTTTTTCTTTGTTTGT	1080
Dd	1021	AACCTTGACTTTCAAGATAATTTTTCAGGGTTTTTGTGCTGTTGTTTTTCTTTGTTTGT	1080
Qy	1081	TTGCTGGGAGAGGGGAGGGATGCTCGGGAAGTGGTTAAACAACCTTTTTCCAAGTCACCTTTA	1140
Dd	1081	TTGCTGGGAGAGGGGAGGGATGCTCGGGAAGTGGTTAAACAACCTTTTTCCAAGTCACCTTTA	1140
Qy	1141	CTAAAAAACHTTTGTAAAA TAGACCTTACCTTCTATTTTCGAGTTTCAATTAATTTTTCG	1200
Dd	1141	CTAAAAAACHTTTGTAAAA TAGACCTTACCTTCTATTTTCGAGTTTCAATTAATTTTTCG	1200
Qy	1201	AGTGTAGCAGCCTCATCAAGAAGCTGCATTTACTCATTTGACTTTTGCACCTGACTGTATT	1260
Dd	1201	AGTGTAGCAGCCTCATCAAGAAGCTGCATTTACTCATTTGACTTTTGCACCTGACTGTATT	1260
Qy	1261	ATCTGGGTATCTGTGTGTGTCGACTTCATGGTAAAC GGGATCTAAAAAGCTGGTGGCT	1320
Dd	1261	ATCTGGGTATCTGTGTGTGTCGACTTCATGGTAAAC GGGATCTAAAAAGCTGGTGGCT	1320
Qy	1321	TTTTCAAAAAGACAGATTTTCTTCACTGTCATGTCATGTCGTCGATGTCGTCGATGATCTAGAAC	1380
Dd	1321	TTTTCAAAAAGACAGATTTTCTTCACTGTCATGTCATGTCGTCGATGTCGTCGATGATCTAGAAC	1380
Qy	1381	AAACTGGCCATTTGCTAGTTTACTCTTAAAGACTAAACATAGTCTTTGGTGTGTGGTCTTT	1440
Dd	1381	AAACTGGCCATTTGCTAGTTTACTCTTAAAGACTAAACATAGTCTTTGGTGTGTGGTCTTT	1440
Qy	1441	ACTCATCTTCTAGTACCTTTTAAGACAAATCCCTAAGGACTTTGGACCTTTCGCAATAAGAA	1500
Dd	1441	ACTCATCTTCTAGTACCTTTTAAGACAAATCCCTAAGGACTTTGGACCTTTCGCAATAAGAA	1500
Qy	1501	ATTTTATTTTAAAA CCCAAGCCTCCCTGGATTTGATAATATATACATTTTGTACAGCATTTTC	1560

PR	10-JUN-1998;	98US-0088734P.	XX
DR	10-JUN-1998;	98US-0088738P.	DR
PR	10-JUN-1998;	98US-0088742P.	PR
XX	10-JUN-1998;	98US-0088810P.	XX
PT	10-JUN-1998;	98US-0088824P.	PT
PT	10-JUN-1998;	98US-0088826P.	PT
PT	11-JUN-1998;	98US-0088858P.	PT
XX	11-JUN-1998;	98US-0088861P.	XX
PS	11-JUN-1998;	98US-0088875P.	PS
XX	12-JUN-1998;	98US-0089105P.	XX
XX	16-JUN-1998;	98US-0089440P.	XX
CC	16-JUN-1998;	98US-0089513P.	CC
CC	16-JUN-1998;	98US-0089514P.	CC
CC	17-JUN-1998;	98US-0089532P.	CC
CC	17-JUN-1998;	98US-0089538P.	CC
CC	17-JUN-1998;	98US-0089598P.	CC
CC	17-JUN-1998;	98US-0089599P.	CC
CC	17-JUN-1998;	98US-0089600P.	CC
CC	17-JUN-1998;	98US-0089653P.	CC
CC	18-JUN-1998;	98US-0089801P.	CC
CC	18-JUN-1998;	98US-0089907P.	CC
CC	18-JUN-1998;	98US-0089908P.	CC
CC	16-SEP-1998;	98WO-US0119330.	CC
CC	17-SEP-1998;	98WO-US0119437.	CC
CC	07-OCT-1998;	98WO-US021141.	CC
CC	01-DEC-1998;	98WO-US025108.	CC
CC	05-JAN-1999;	99WO-US000106.	CC
CC	08-MAR-1999;	99WO-US005038.	CC
CC	02-JUN-1999;	99WO-US012252.	CC
CC	15-SEP-1999;	99WO-US021090.	CC
CC	15-SEP-1999;	99WO-US021547.	CC
CC	30-NOV-1999;	99WO-US028313.	CC
CC	01-DEC-1999;	99WO-US028301.	CC
CC	01-DEC-1999;	99WO-US028634.	CC
CC	16-DEC-1999;	99WO-US030095.	CC
CC	20-DEC-1999;	99WO-US030911.	CC
CC	06-JAN-2000;	2000WO-US000219.	CC
CC	06-JAN-2000;	2000WO-US000376.	CC
CC	11-FEB-2000;	2000WO-US003565.	CC
CC	18-FEB-2000;	2000WO-US004341.	CC
CC	22-FEB-2000;	2000WO-US004114.	CC
CC	24-FEB-2000;	2000WO-US004914.	CC
CC	24-FEB-2000;	2000WO-US005094.	CC
CC	02-MAR-2000;	2000WO-US005841.	CC
CC	10-MAR-2000;	2000WO-US006319.	CC
CC	15-MAR-2000;	2000WO-US006894.	CC
CC	20-MAR-2000;	2000WO-US007377.	CC
CC	30-MAR-2000;	2000WO-US008439.	CC
CC	15-MAY-2000;	2000WO-US013358.	CC
CC	17-MAY-2000;	2000WO-US013705.	CC
CC	22-MAY-2000;	2000WO-US014042.	CC
CC	30-MAY-2000;	2000WO-US014941.	CC
CC	02-JUN-2000;	2000WO-US015284.	CC
CC	28-JUL-2000;	2000WO-US020710.	CC
CC	11-AUG-2000;	2000WO-US022031.	CC
CC	23-AUG-2000;	2000WO-US023522.	CC
CC	24-AUG-2000;	2000WO-US023328.	CC
CC	08-NOV-2000;	2000WO-US030952.	CC
CC	01-DEC-2000;	2000WO-US032678.	CC
CC	28-FEB-2001;	2001WO-US006520.	CC
CC	01-JUN-2001;	2001WO-US017800.	CC
CC	20-JUN-2001;	2001WO-US019692.	CC
CC	29-JUN-2001;	2001WO-US021066.	CC
CC	09-JUL-2001;	2001WO-US021735.	CC
CC	28-AUG-2001;	2001US-00941992.	CC
XX			XX
PA	(GETH) GENENTECH INC.		PA
XX			XX
XX	Askenazi AJ, Baker KP, Botstein D, Desnoyers L, Eaton DL;		XX
XX	Ferrara N, Fong S, Gerber H, Gerritsen ME, Goddard A, Godowski PJ;		XX
XX	Grimaldi JC, Gurney AL, Napier MA, Pan J, Paoi NF;		XX
XX	Roy MA, Stewart TA, Tumas D, Watanabe CK, Williams PM, Wood WI;		XX
XX	Zhang Z;		XX

12-AUG-1998;	98US-00963223P;
17-AUG-1998;	98US-00967516P;
17-AUG-1998;	98US-00967666P;
17-AUG-1998;	98US-00967669P;
17-AUG-1998;	98US-00967733P;
17-AUG-1998;	98US-00967911P;
17-AUG-1998;	98US-00968671P;
17-AUG-1998;	98US-00968691P;
17-AUG-1998;	98US-00968914P;
17-AUG-1998;	98US-00968935P;
17-AUG-1998;	98US-00968971P;
18-AUG-1998;	98US-00969499P;
18-AUG-1998;	98US-00969509P;
18-AUG-1998;	98US-00969602P;
18-AUG-1998;	98US-00970222P;
19-AUG-1998;	98US-00971411P;
20-AUG-1998;	98US-00972161P;
24-AUG-1998;	98US-00976616P;
26-AUG-1998;	98US-00979524P;
26-AUG-1998;	98US-00979544P;
26-AUG-1998;	98US-00979556P;
26-AUG-1998;	98US-00979711P;
26-AUG-1998;	98US-00979744P;
26-AUG-1998;	98US-00979791P;
26-AUG-1998;	98US-00979792P;
26-AUG-1998;	98US-00979864P;
26-AUG-1998;	98US-00980141P;
31-AUG-1998;	98US-01006344P;
16-SEP-1998;	98WO-US019330P;
17-SEP-1998;	98WO-US019437P;
17-SEP-1998;	98WO-US019437P;
17-OCT-1998;	98WO-US021141P;
01-DEC-1998;	98WO-US0295108P;
21-DEC-1998;	98US-01132366P;
05-JAN-1999;	99WO-US0001010P;
08-MAR-1999;	99WO-US0050528P;
12-MAR-1999;	99US-01239577P;
02-JUN-1999;	99WO-US012252P;
22-JUN-1999;	99US-01410733P;
08-OCT-1999;	99US-01430408P;
20-NOV-1999;	99US-01447588P;
20-JUL-1999;	99US-01456982P;
26-JUL-1999;	99US-01482222P;
28-JUL-1999;	99US-01493596P;
17-AUG-1999;	99WO-US021090P;
15-SEP-1999;	99WO-US021547P;
15-SEP-1999;	99US-01586663P;
30-NOV-1999;	99WO-US028313P;
01-DEC-1999;	99WO-US028301P;
16-DEC-1999;	99WO-US028634P;
20-DEC-1999;	99WO-US030095P;
05-JAN-2000;	99WO-US030911P;
06-JAN-2000;	2000WO-US000219P;
11-FEB-2000;	2000WO-US003076P;
22-FEB-2000;	2000WO-US003565P;
18-FEB-2000;	2000WO-US004341P;
22-FEB-2000;	2000WO-US004414P;
24-FEB-2000;	2000WO-US004914P;
02-MAR-2000;	2000WO-US005004P;
10-MAR-2000;	2000WO-US005384P;
15-MAR-2000;	2000WO-US006319P;
20-MAR-2000;	2000WO-US006684P;
30-MAR-2000;	2000WO-US007377P;
15-MAY-2000;	2000WO-US008439P;
17-MAY-2000;	2000WO-US013358P;
22-MAY-2000;	2000WO-US013705P;
30-MAY-2000;	2000WO-US014042P;
02-JUN-2000;	2000WO-US014941P;
23-JUN-2000;	2000WO-US015264P;
28-JUN-2000;	2000US-02136377P;
28-JUL-2000;	2000WO-US020710P;

421 AATTATCTCTCCATTTTGGGCTTCTACTCTGTACATGGTATATCTTACTCTGGTGA 480
481 GCCCATCTAGAGAGGGGCTCTTTGGACATGCACAGTTGATACAGAGTATGATAT 540
481 GCCCATCTAGAGAGGGGCTCTTTGGACATGCACAGTTGATACAGAGTATGATAT 540
541 TGGGGATCACAGCCTTTTGCCTTAAATGACACAGATGTCTAGCCGCTCCGGAGTCGAGC 600
541 TGGGGATCACAGCCTTTTGCCTTAAATGACACAGATGTCTAGCCGCTCCGGAGTCGAGC 600
601 CAACGTGCTGAAACAAGTATGATGACACAGCAGCTGGAAGCTTCAAGTCCAAAGACA 660
601 CAACGTGCTGAAACAAGTATGATGACACAGCAGCTGGAAGCTTCAAGTCCAAAGACA 660
661 GCGAAGTCTGTCTTGAACGGCATGTGTCTCAGCTAATTTGGGAATGAATTCAGGT 720
661 GCGAAGTCTGTCTTGAACGGCATGTGTCTCAGCTAATTTGGGAATGAATTCAGGT 720
721 GACTAGAAAGAAACAGGACAGCAACTGGAAGAACTGACTGGGTTTTGCTGGGTTTCATT 780
721 GACTAGAAAGAAACAGGACAGCAACTGGAAGAACTGACTGGGTTTTGCTGGGTTTCATT 780
781 TTAATACCTTGTGATTTACCAACTGTTGCTGGAAGATTTCAAACTGGAAGCAAAACT 840
781 TTAATACCTTGTGATTTACCAACTGTTGCTGGAAGATTTCAAACTGGAAGCAAAACT 840
841 TGCTTGATTTTTTTTCTTTTAACTGATTAATAGAGACATTTTAAAGACACAGCTC 900
841 TGCTTGATTTTTTTTCTTTTAACTGATTAATAGAGACATTTTAAAGACACAGCTC 900
901 AAGTCAGCAATAAGCTTTTCTTCTTAACTGATTTTCTTAAATAAATAATCTGCT 960
901 AAGTCAGCAATAAGCTTTTCTTCTTAACTGATTTTCTTAAATAAATAATCTGCT 960
961 GTAAATATCTTGAAGTCTTTTACCTGGAAGCACTCTCTTTTCCACACATGTTT 1020
961 GTAAATATCTTGAAGTCTTTTACCTGGAAGCACTCTCTTTTCCACACATGTTT 1020
1021 AACTTGACTTCAAGATAATTTTCAAGGTTTTTGTGTTGTTTGTGTTTGTGTTTGT 1080
1021 AACTTGACTTCAAGATAATTTTCAAGGTTTTTGTGTTGTTTGTGTTTGTGTTTGT 1080
1081 TTGGTGGAGAGGGAGGGATGCTGGAGTGTGTTAACTTTTCAAGTCACTTTA 1140
1081 TTGGTGGAGAGGGAGGGATGCTGGAGTGTGTTAACTTTTCAAGTCACTTTA 1140
1141 CTAAACAAACTTTTGTAAATAGACCTTACCTTCTATTTTTCGAGTTTCAATTTATTTG 1200
1141 CTAAACAAACTTTTGTAAATAGACCTTACCTTCTATTTTTCGAGTTTCAATTTATTTG 1200
1201 AGTGTAGCAGCCTCATCAAGAGCTGACTTACTCATTTTGTGCTGCTGCTGATTT 1260
1201 AGTGTAGCAGCCTCATCAAGAGCTGACTTACTCATTTTGTGCTGCTGCTGATTT 1260
1261 ATCTGGTATCTGCTGTCTGCTCATCTGATGTTGTTGTTGTTGTTGTTGTTGTTG 1320
1261 ATCTGGTATCTGCTGTCTGCTCATCTGATGTTGTTGTTGTTGTTGTTGTTGTTG 1320
1321 TTTCAAAAAGCAGATTTTCTTCACTGATGCTGATGCTGATGCTGATGCTGATGCT 1380
1321 TTTCAAAAAGCAGATTTTCTTCACTGATGCTGATGCTGATGCTGATGCTGATGCT 1380
1381 AAACGGCATTGCTAGTTTACTCTTAAAGACTTAAACATAGTCTGCTGCTGCTGCT 1440
1381 AAACGGCATTGCTAGTTTACTCTTAAAGACTTAAACATAGTCTGCTGCTGCTGCT 1440
1441 ACTCATCTTCTAGTACTTTTAAAGCAAACTTCAAGGACTTGGACATTTGCAATAAGAA 1500
1441 ACTCATCTTCTAGTACTTTTAAAGCAAACTTCAAGGACTTGGACATTTGCAATAAGAA 1500
1501 AATTATTTTAAACCAAGCCTCCCTGGATGATATATATACATTTTGTGAGATTTTC 1560

1501 ATTTTATTTTAAACCAAGCCTCCCTGGATGATATATATACATTTTGTGAGATTTTC 1560
1561 CGGTGCTGCTGAGAGGAGCTGTTTGGAGCTTCAATATGTGTGAGCTTTGAACTAGGGCTGG 1620
1561 CGGTGCTGCTGAGAGGAGCTGTTTGGAGCTTCAATATGTGTGAGCTTTGAACTAGGGCTGG 1620
1621 GGTGTGGTGGCTCTTCTTGAAGGCTTAAACATTTATTTGGATAACTGGCTTTTCTTCTCC 1680
1621 GGTGTGGTGGCTCTTCTTGAAGGCTTAAACATTTATTTGGATAACTGGCTTTTCTTCTCC 1680
1681 TATGTCTCTTTTGAATGATTAACAATAAATAATTTTGTAAACATCAA 1728
1681 TATGTCTCTTTTGAATGATTAACAATAAATAATTTTGTAAACATCAA 1728

RESULT 11
ID ACA64436 standard; cDNA; 1728 BP.
AC ACA64436;
XX
DT 17-JUN-2003 (first entry)
XX
DE Novel human secreted and transmembrane protein PRO1375 cDNA.
XX
KW Human; secreted and transmembrane protein; cytostatic; anti-HIV;
KW virucide; hepatotropic; antiinflammatory; neuroprotective; gene therapy;
KW PRO; pharmaceutical; diagnostic; biosensor; bioreactor; malignancy;
KW cancer; ovarian cancer; colorectal cancer; Kaposi's sarcoma; leukaemia;
KW lymphoma; hepatitis B; multiple sclerosis; Crohn's disease;
KW drug screening; Gene; ss.
XX
OS Homo sapiens.
XX
PN US2003003531-A1.
XX
PD 02-JAN-2003.
XX
PF 19-NOV-2001; 2001US-00989734.
XX
PR 16-JUN-1997; 97US-0049787P.
PR 17-OCT-1997; 97US-0062250P.
PR 05-NOV-1997; 97WO-US020069.
PR 12-NOV-1997; 97US-0065186P.
PR 13-NOV-1997; 97US-0065311P.
PR 24-NOV-1997; 97US-0066770P.
PR 25-FEB-1998; 98US-0075945P.
PR 20-MAR-1998; 98US-0078910P.
PR 28-APR-1998; 98US-0083322P.
PR 07-MAY-1998; 98US-0084600P.
PR 28-MAY-1998; 98US-0087106P.
PR 02-JUN-1998; 98US-0087607P.
PR 02-JUN-1998; 98US-0087609P.
PR 03-JUN-1998; 98US-0087759P.
PR 04-JUN-1998; 98US-0087827P.
PR 04-JUN-1998; 98US-0088021P.
PR 04-JUN-1998; 98US-0088025P.
PR 04-JUN-1998; 98US-0088026P.
PR 04-JUN-1998; 98US-0088028P.
PR 04-JUN-1998; 98US-0088029P.
PR 04-JUN-1998; 98US-0088030P.
PR 04-JUN-1998; 98US-0088033P.
PR 04-JUN-1998; 98US-0088326P.
PR 05-JUN-1998; 98US-0088167P.
PR 05-JUN-1998; 98US-0088202P.
PR 05-JUN-1998; 98US-0088212P.
PR 05-JUN-1998; 98US-0088217P.
PR 09-JUN-1998; 98US-0088655P.
PR 10-JUN-1998; 98US-0088734P.
PR 10-JUN-1998; 98US-0088738P.
PR 10-JUN-1998; 98US-0088742P.
PR 10-JUN-1998; 98US-0088810P.
PR 10-JUN-1998; 98US-0088824P.

Dbb 601 CAACTGCTGTAACAAGGTAGATATGCAACAGAGCGCTGGAAGCTTCAAGTCCAAAGACA 660
QY 661 GCGAAAGTCTGTTTGTACCGGCGATGTTCTCTCAGCTAAATTTGGGAATTTGAATTCAGGT 720
Dbb 661 GCGAAAGTCTGTTTGTACCGGCGATGTTCTCTCAGCTAAATTTGGGAATTTGAATTCAGGT 720
QY 721 GACTAGAAAGAACAGCGACAGCACTGGAAGCACTGACTGGTGTGTTTCTGCTGGTTCATT 780
Dbb 721 GACTAGAAAGAACAGCGACAGCACTGGAAGCACTGACTGGTGTGTTTCTGCTGGTTCATT 780
QY 781 TTAATACCTTGTGATTTTCAACCACTGTTGCTGGAAGATTCAAAACCTGGAAGCAAAAAC 840
Dbb 781 TTAATACCTTGTGATTTTCAACCACTGTTGCTGGAAGATTCAAAACCTGGAAGCAAAAAC 840
QY 841 TCGTCAATTTTCTGTTTAAAGTAACTAATAGAGCACTTTTAAAGCAACAGCTC 900
Dbb 841 TCGTCAATTTTCTGTTTAAAGTAACTAATAGAGCACTTTTAAAGCAACAGCTC 900
QY 901 AAGTCAAGCAATAAGCTTTTCCATTTTGTGACCTTTTACTAATAAATAAATCTGCT 960
Dbb 901 AAGTCAAGCAATAAGCTTTTCCATTTTGTGACCTTTTACTAATAAATAAATCTGCT 960
QY 961 GTAATAATCTGTAAGTCTTTTACCTGGAACAGCACTCTCTTTTCCACCATAGTATT 1020
Dbb 961 GTAATAATCTGTAAGTCTTTTACCTGGAACAGCACTCTCTTTTCCACCATAGTATT 1020
QY 1021 AACTTGACCTTCAAGATAATTTTCAAGGTTTGTGTTGTTGTTTGTGTTTGTGTT 1080
Dbb 1021 AACTTGACCTTCAAGATAATTTTCAAGGTTTGTGTTGTTGTTTGTGTTTGTGTT 1080
QY 1081 TTGGTGGGAGAGGGAGGATCCCTGGGAAGTGGTTAAACAATTTTCAAGTCACTTTA 1140
Dbb 1081 TTGGTGGGAGAGGGAGGATCCCTGGGAAGTGGTTAAACAATTTTCAAGTCACTTTA 1140
QY 1141 CTAAACAACCTTTTGTAAATAGACCTTACCTTCTAATTTTCGAGTTTCATTATATTTGC 1200
Dbb 1141 CTAAACAACCTTTTGTAAATAGACCTTACCTTCTAATTTTCGAGTTTCATTATATTTGC 1200
QY 1201 AGTGTAGCAGCTCATCAAGAGCTGACTTACTCATTTGACTTTTGCACGTACTTAT 1260
Dbb 1201 AGTGTAGCAGCTCATCAAGAGCTGACTTACTCATTTGACTTTTGCACGTACTTAT 1260
QY 1261 ACTGGGTATCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 1320
Dbb 1261 ACTGGGTATCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 1320
QY 1321 TTTTCAAAAAGCAGATTTTCTTCTGATGCTGATGCTGATGCTGATGCTGATGCTGATGCT 1380
Dbb 1321 TTTTCAAAAAGCAGATTTTCTTCTGATGCTGATGCTGATGCTGATGCTGATGCTGATGCT 1380
QY 1381 AAATGGCCATTTGCTAGTTTACTCTAAGACATAAATAGTCTTGGTGTGTTGGTCTT 1440
Dbb 1381 AAATGGCCATTTGCTAGTTTACTCTAAGACATAAATAGTCTTGGTGTGTTGGTCTT 1440
QY 1441 ACTCATCTTCTAGTACCTTTAAGGACAAATCCTAAGGACTTGGACACTTGGCAATAAGAA 1500
Dbb 1441 ACTCATCTTCTAGTACCTTTAAGGACAAATCCTAAGGACTTGGACACTTGGCAATAAGAA 1500
QY 1501 ATTTTATTTTAAACCAAGCTTCCCTGGATGATATATATACATTTGTCAGATTTT 1560
Dbb 1501 ATTTTATTTTAAACCAAGCTTCCCTGGATGATATATATACATTTGTCAGATTTT 1560
QY 1561 CGGTCTGCTGAGAGCGCTCTTTGAGCTCCATATGTCAGCTTTGAACTAGGCTGG 1620
Dbb 1561 CGGTCTGCTGAGAGCGCTCTTTGAGCTCCATATGTCAGCTTTGAACTAGGCTGG 1620
QY 1621 GGTGTGGGTGCTCTTCTGAAAGGTCTAACCATTTATGGAATACTGGCTTTTCTTCC 1680
Dbb 1621 GGTGTGGGTGCTCTTCTGAAAGGTCTAACCATTTATGGAATACTGGCTTTTCTTCC 1680
QY 1681 TATGTCCTCTTTGGAATTAACAATAAATAATTTTGAACATCAA 1728
Dbb 1681 TATGTCCTCTTTGGAATTAACAATAAATAATTTTGAACATCAA 1728

RESULT 12
ACA58005
ID ACA58005 standard; cDNA; 1728 BP.

XX ACA58005;

AC ACA58005;

XX 09-JUN-2003 (first entry)

XX cDNA encoding human neoplasia inhibiting PRO polypeptide PRO1375.

Human; ss; gene; tumour; cancer; neoplasia; liver cancer; sarcoma;
breast cancer; ovarian cancer; renal cancer; colorectal cancer; melanoma;
uterine cancer; prostate cancer; lung cancer; bladder cancer; leukaemia;
gastric cancer; pancreatic cancer; vulval cancer; thyroid cancer;
central nervous system cancer; hepatic carcinoma; glioblastoma;
neural disorder; glial disorder; astrocytal disorder;
hypothalamic disorder; glandular disorder; macrophagal disorder;
epithelial disorder; stromal disorder; blastocoelec disorder;
inflammatory disorder; angiogenic disorder; immunologic disorder.

XX Homo sapiens.

OS US2002192209-A1.

XX 19-DEC-2002.

XX 30-NOV-2001; 2001US-00001054.

XX 17-SEP-1997; 97US-0059114P.

PR 27-MAR-1998; 98US-0079689P.

PR 30-MAR-1998; 98US-0079920P.

PR 24-APR-1998; 98US-0082999P.

PR 29-APR-1998; 98US-0083545P.

PR 12-MAY-1998; 98US-0085149P.

PR 02-JUN-1998; 98US-0087607P.

PR 11-JUN-1998; 98US-0088588P.

PR 25-JUN-1998; 98US-0090691P.

PR 17-AUG-1998; 98US-0096891P.

PR 10-SEP-1998; 98US-0099803P.

PR 14-SEP-1998; 98US-0100263P.

PR 15-SEP-1998; 98US-0100390P.

PR 23-SEP-1998; 98US-0101476P.

PR 10-NOV-1998; 98US-0107783P.

PR 19-NOV-1998; 98US-0108499P.

PR 15-DEC-1998; 98US-0112420P.

PR 22-DEC-1998; 98US-00218517.

PR 22-DEC-1998; 98US-0113296P.

PR 05-JAN-1999; 99WO-US000106.

PR 12-JAN-1999; 99US-0115554P.

PR 20-JAN-1999; 99US-0115558P.

PR 08-MAR-1999; 99WO-US005028.

PR 10-MAR-1999; 99US-0123618P.

PR 12-APR-1999; 99US-00284291.

PR 20-APR-1999; 99WO-US008615.

PR 27-APR-1999; 99US-0131294P.

PR 02-JUN-1999; 99WO-US013252.

PR 22-JUN-1999; 99US-0140650P.

PR 23-JUN-1999; 99US-0141037P.

PR 20-JUL-1999; 99US-0144758P.

PR 25-AUG-1999; 99US-00380137.

PR 25-AUG-1999; 99US-00380138.

PR 01-SEP-1999; 99WO-US020111.

PR 08-SEP-1999; 99WO-US020594.

PR 09-SEP-1999; 99US-00380913.

PR 18-OCT-1999; 99US-00403297.

PR 29-OCT-1999; 99US-0162506P.

PR 10-NOV-1999; 99US-00423741.

Db 901 AAAGTCAGCCAAATAGCTTTTCTTCTATTTGTGACITTTTACTAATAAATAATATCTGCCT 960
QY 961 GTAATAATCTTGAAGCTCTTTACCTGGAAACAGACTCTCTTTTTCACCAATAGTTT 1020
Db 961 GTAATAATCTTGAAGCTCTTTACCTGGAAACAGACTCTCTTTTTCACCAATAGTTT 1020
QY 1021 AACTTGACCTTCAAGATAATTTTCAGGGTTTGTGTTGTTGTTGTTGTTGTTGTTGTT 1080
Db 1021 AACTTGACCTTCAAGATAATTTTCAGGGTTTGTGTTGTTGTTGTTGTTGTTGTTGTT 1080
QY 1081 TTGGTGGGAGAGGGAGGAGCTGGGAAGTGGTTAAACAATTTTTCAGTCACTTTA 1140
Db 1081 TTGGTGGGAGAGGGAGGAGCTGGGAAGTGGTTAAACAATTTTTCAGTCACTTTA 1140
QY 1141 CTAAACAACCTTTTGTAAATAGACCTTACTCTTATTTTCGAGTTTCATTATATTTGTC 1200
Db 1141 CTAAACAACCTTTTGTAAATAGACCTTACTCTTATTTTCGAGTTTCATTATATTTGTC 1200
QY 1201 AGTGTAGCCAGCTCATCAAGAGCTGACTTACTCACTTTGCACTGACTGATTT 1260
Db 1201 AGTGTAGCCAGCTCATCAAGAGCTGACTTACTCACTTTGCACTGACTGATTT 1260
QY 1261 ATCTGGTATCTCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 1320
Db 1261 ATCTGGTATCTCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 1320
QY 1321 TTTTCAAAAAGCAGATTTTCTTCATGTACTGTGTGTGTGTGTGTGTGTGTGTGTGTGT 1380
Db 1321 TTTTCAAAAAGCAGATTTTCTTCATGTACTGTGTGTGTGTGTGTGTGTGTGTGTGT 1380
QY 1381 AAAGTGGCAATTTGCTAGTTTACTCTAAAGACTGACTTACTCACTTTGCACTGACTGATTT 1440
Db 1381 AAAGTGGCAATTTGCTAGTTTACTCTAAAGACTGACTTACTCACTTTGCACTGACTGATTT 1440
QY 1441 ACTCATCTTCTAGTACTCTTTAAGGACAAATCTTAAGGACTTGGACACTTGGCAATAAGAA 1500
Db 1441 ACTCATCTTCTAGTACTCTTTAAGGACAAATCTTAAGGACTTGGACACTTGGCAATAAGAA 1500
QY 1501 ATTTTATTTTAAACCAAGCTCCCTGGATGTAATATATATATATATATATATATATATAT 1560
Db 1501 ATTTTATTTTAAACCAAGCTCCCTGGATGTAATATATATATATATATATATATATATAT 1560
QY 1561 CGGTGCTGTGTGAGAGCAGCTGTTTTCAGCTTCAATATGTCAGCTTTGAACCTAGGCTGG 1620
Db 1561 CGGTGCTGTGTGAGAGCAGCTGTTTTCAGCTTCAATATGTCAGCTTTGAACCTAGGCTGG 1620
QY 1621 GGTGTGGGGTCCCTCTTCTGAAAGGCTAACCAATATGGAATACTGCTTTTCTTCTCC 1680
Db 1621 GGTGTGGGGTCCCTCTTCTGAAAGGCTAACCAATATGGAATACTGCTTTTCTTCTCC 1680
QY 1681 TATGTCTCTTTTGAATGTAACATAAATAATATTTTGAACATCAA 1728
Db 1681 TATGTCTCTTTTGAATGTAACATAAATAATATTTTGAACATCAA 1728

RESULT 13
ABX80895
ID ABX80895 standard; cDNA; 1728 BP.
XX
AC ABX80895;
XX
DT 22-APR-2003 (first entry)
XX
DE Human secreted/transmembrane protein CDNA, #168.
XX
KW Human; gene; ss; PRO; secreted; transmembrane; pharmaceutical;
KW diagnostic; biosensor; bioreactor; tumour; therapeutic; gene therapy;
KW tumour-associated antigenic target; TAR; ADEPT;
KW antibody-dependent enzyme mediated prodrug therapy; cytostatic.
OS Homo sapiens.
XX
PN US2003027162-A1.

XX 06-FEB-2003.
PD
XX 15-NOV-2001; 2001US-009997428.
PF
XX 16-JUN-1997; 97US-0049787P.
PR 17-OCT-1997; 97US-0062250P.
PR 05-NOV-1997; 97WO-US020069.
PR 12-NOV-1997; 97US-0065186P.
PR 13-NOV-1997; 97US-0065311P.
PR 24-NOV-1997; 97US-0066770P.
PR 25-FEB-1998; 98US-0075945P.
PR 20-MAR-1998; 98US-0078910P.
PR 28-APR-1998; 98US-0083322P.
PR 07-MAY-1998; 98US-0084600P.
PR 28-MAY-1998; 98US-0087106P.
PR 02-JUN-1998; 98US-0087607P.
PR 02-JUN-1998; 98US-0087609P.
PR 02-JUN-1998; 98US-0087759P.
PR 03-JUN-1998; 98US-0087827P.
PR 04-JUN-1998; 98US-0088021P.
PR 04-JUN-1998; 98US-0088025P.
PR 04-JUN-1998; 98US-0088026P.
PR 04-JUN-1998; 98US-0088028P.
PR 04-JUN-1998; 98US-0088029P.
PR 04-JUN-1998; 98US-0088030P.
PR 04-JUN-1998; 98US-0088033P.
PR 04-JUN-1998; 98US-0088326P.
PR 05-JUN-1998; 98US-0088167P.
PR 05-JUN-1998; 98US-0088202P.
PR 05-JUN-1998; 98US-0088212P.
PR 05-JUN-1998; 98US-0088217P.
PR 09-JUN-1998; 98US-0088655P.
PR 10-JUN-1998; 98US-0088734P.
PR 10-JUN-1998; 98US-0088738P.
PR 10-JUN-1998; 98US-0088742P.
PR 10-JUN-1998; 98US-0088810P.
PR 10-JUN-1998; 98US-0088824P.
PR 10-JUN-1998; 98US-0088826P.
PR 11-JUN-1998; 98US-0088856P.
PR 11-JUN-1998; 98US-0088861P.
PR 11-JUN-1998; 98US-0088876P.
PR 12-JUN-1998; 98US-0089105P.
PR 16-JUN-1998; 98US-0089440P.
PR 16-JUN-1998; 98US-0089512P.
PR 16-JUN-1998; 98US-0089514P.
PR 17-JUN-1998; 98US-0089532P.
PR 17-JUN-1998; 98US-0089538P.
PR 17-JUN-1998; 98US-0089598P.
PR 17-JUN-1998; 98US-0089599P.
PR 17-JUN-1998; 98US-0089600P.
PR 17-JUN-1998; 98US-0089653P.
PR 18-JUN-1998; 98US-0089907P.
PR 18-JUN-1998; 98US-0089901P.
PR 18-JUN-1998; 98US-0089908P.
PR 19-JUN-1998; 98US-0089947P.
PR 19-JUN-1998; 98US-0089948P.
PR 19-JUN-1998; 98US-0089952P.
PR 22-JUN-1998; 98US-0090246P.
PR 22-JUN-1998; 98US-0090252P.
PR 22-JUN-1998; 98US-0090254P.
PR 23-JUN-1998; 98US-0090349P.
PR 23-JUN-1998; 98US-0090355P.
PR 24-JUN-1998; 98US-0090429P.
PR 24-JUN-1998; 98US-0090431P.
PR 24-JUN-1998; 98US-0090435P.
PR 24-JUN-1998; 98US-0090444P.
PR 24-JUN-1998; 98US-0090445P.
PR 24-JUN-1998; 98US-0090472P.
PR 24-JUN-1998; 98US-0090535P.
PR 24-JUN-1998; 98US-0090540P.
PR 24-JUN-1998; 98US-0090542P.
PR 24-JUN-1998; 98US-0090557P.

421 AATTTATCTCTCCATTTTGGGCTCTACTTCTGTACATGGTATATCTTACTCTCGTTGA 480
481 GCCCATCTGACAGAGCGGCTCTTTGGACATGCACAGTTGATACAGAGTGATGATAT 540
481 GCCCATCTGACAGAGCGGCTCTTTGGACATGCACAGTTGATACAGAGTGATGATAT 540
541 TGGGATCACCAAGCTTTTGCATTAATGCACACAGATGCTAGCCCGCTCCCGAGTCGAGC 600
541 TGGGATCACCAAGCTTTTGCATTAATGCACACAGATGCTAGCCCGCTCCCGAGTCGAGC 600
601 CAACGTCTGTAACAAGTGAATATGCACAGAGCGCTGGAAGCTTCAAGTCCAGAGCA 660
601 CAACGTCTGTAACAAGTGAATATGCACAGAGCGCTGGAAGCTTCAAGTCCAGAGCA 660
661 GCGAAAGTCTGTCTTTGACCGCATGTTCTCTCAGCTAATTTGGGAATGAATCAAGCT 720
661 GCGAAAGTCTGTCTTTGACCGCATGTTCTCTCAGCTAATTTGGGAATGAATCAAGCT 720
721 GACTAGAAAGAACAGGCGAGCAAACTGGAAGAACTGACTGGGTTTGTCTGGGTTTCATT 780
721 GACTAGAAAGAACAGGCGAGCAAACTGGAAGAACTGACTGGGTTTGTCTGGGTTTCATT 780
781 TTAATACCTTGTGATTTTCAACCACTGTTGCTGGAGATTTCAAACTGGAAGCAAAACT 840
781 TTAATACCTTGTGATTTTCAACCACTGTTGCTGGAGATTTCAAACTGGAAGCAAAACT 840
841 TGCTTGATTTTTTTTCTTTGTTAAACGTAATAATAGAGACATTTTAAAGACACAGCTC 900
841 TGCTTGATTTTTTTTCTTTGTTAAACGTAATAATAGAGACATTTTAAAGACACAGCTC 900
901 AAGTCAGCCAAATAGTCTTTCTCTATTTGTGACTTTTACTAATAAATAATCTGCT 960
901 AAGTCAGCCAAATAGTCTTTCTCTATTTGTGACTTTTACTAATAAATAATCTGCT 960
961 GTAAATATCTTGAAGTCTTTTACCTGGAACAGCACTCTCTTTTTCACCATAGTTT 1020
961 GTAAATATCTTGAAGTCTTTTACCTGGAACAGCACTCTCTTTTTCACCATAGTTT 1020
1021 AACTTGACTTCAAGATAATTTTCAAGGTTTGTGTTGTTGTTTGTGTTTGTGTTTGT 1080
1021 AACTTGACTTCAAGATAATTTTCAAGGTTTGTGTTGTTGTTTGTGTTTGTGTTTGT 1080
1081 TTGGTGGGAGGGGAGGATGCTGGGAGTGGTTAAACAATTTTCAAGTCACTTTA 1140
1081 TTGGTGGGAGGGGAGGAGTGGTGGGAGTGGTTAAACAATTTTCAAGTCACTTTA 1140
1141 CTAACAACAATTTTGAATAATAGACCTTACCTTCTATTTTTCGAGTTTCATTATTTTC 1200
1141 CTAACAACAATTTTGAATAATAGACCTTACCTTCTATTTTTCGAGTTTCATTATTTTC 1200
1201 AGTGTAGCAGCTCATCAAGAGCTGACTTACTCATTTTGCATTTTGCATGCTGATTT 1260
1201 AGTGTAGCAGCTCATCAAGAGCTGACTTACTCATTTTGCATTTTGCATGCTGATTT 1260
1261 ATCTGGGTATCTCTGTGTCTGACTTCAATGTAATGTAATGTAATGTAATGTAATGTA 1320
1261 ATCTGGGTATCTCTGTGTCTGACTTCAATGTAATGTAATGTAATGTAATGTAATGTA 1320
1321 TTTTCAAAAAGCAGATTTTCTCATGTACTGTGATGCTGATGATGATGATGATGATGAT 1380
1321 TTTTCAAAAAGCAGATTTTCTCATGTACTGTGATGCTGATGATGATGATGATGATGAT 1380
1381 AAATGCGCATTTGCTAGTTTACTCTTAAAGACTTAAACATAGTCTTGGTGTGTGTCTTT 1440
1381 AAATGCGCATTTGCTAGTTTACTCTTAAAGACTTAAACATAGTCTTGGTGTGTGTCTTT 1440
1441 ACTCATCTTCTAGTACCTTTAAGGACAAATCTTAAAGACTTGGACATTTGCAATAAGAA 1500
1441 ACTCATCTTCTAGTACCTTTAAGGACAAATCTTAAAGACTTGGACATTTGCAATAAGAA 1500
1501 ATTTTATTTTAAACCCAGCTCCCTGGATTGATATATATACATATTTGTGAGATTTTC 1560
1501 ATTTTATTTTAAACCCAGCTCCCTGGATTGATATATATACATATTTGTGAGATTTTC 1560

QY 1561 CGGTCTGTGTGAGAGGCGAGCTGTTTGTAGCTCCCAATATGTGCAGCTTTGAACTAGGGCTGG 1620
Db 1561 CGGTCTGTGTGAGAGGCGAGCTGTTTGTAGCTCCCAATATGTGCAGCTTTGAACTAGGGCTGG 1620
QY 1621 GGTGTGGTGGCTCTTCTGAAAGGTCTAAACCAATTTATTTGATTAACCTGGCTTTTCTTCC 1680
Db 1621 GGTGTGGTGGCTCTTCTGAAAGGTCTAAACCAATTTATTTGATTAACCTGGCTTTTCTTCC 1680
QY 1681 TATGTCCTCTTTTGAATGTAAACCAATTAATAATTTTGAACATCAA 1728
Db 1681 TATGTCCTCTTTTGAATGTAAACCAATTAATAATTTTGAACATCAA 1728
RESULT 14
ACD44404
ID ACD44404 standard; cDNA; 1728 BP.
XX ACD44404;
AC ACD44404;
XX
DT 10-SEP-2003 (first entry)
XX
XX cDNA encoding human PRO1375 polypeptide.
DE Human; PRO polypeptide; secreted protein; transmembrane protein;
KW genetic disorder; antibacterial; immunosuppressive; transgenic;
KW Gene therapy; Gene; ss.
XX
OS Homo sapiens.
XX
PN US2002127576-A1.
XX
PD 12-SEP-2002.
XX
PF 14-NOV-2001; 2001US-00991073.
XX
PR 16-JUN-1997; 97US-0049787P.
PR 17-OCT-1997; 97US-0062250P.
PR 05-NOV-1997; 97WO-US020069.
PR 12-NOV-1997; 97US-0085186P.
PR 13-NOV-1997; 97US-0085311P.
PR 24-NOV-1997; 97US-0066770P.
PR 25-FEB-1998; 98US-0075945P.
PR 20-MAR-1998; 98US-0078910P.
PR 28-APR-1998; 98US-0083322P.
PR 07-MAY-1998; 98US-0034600P.
PR 28-MAY-1998; 98US-0087106P.
PR 02-JUN-1998; 98US-0087607P.
PR 02-JUN-1998; 98US-0087609P.
PR 03-JUN-1998; 98US-0087759P.
PR 04-JUN-1998; 98US-0087827P.
PR 04-JUN-1998; 98US-0088021P.
PR 04-JUN-1998; 98US-0088025P.
PR 04-JUN-1998; 98US-0088026P.
PR 04-JUN-1998; 98US-0088029P.
PR 04-JUN-1998; 98US-0088030P.
PR 04-JUN-1998; 98US-0088033P.
PR 04-JUN-1998; 98US-0088326P.
PR 05-JUN-1998; 98US-0088167P.
PR 05-JUN-1998; 98US-0088202P.
PR 05-JUN-1998; 98US-0088212P.
PR 05-JUN-1998; 98US-0088217P.
PR 09-JUN-1998; 98US-0088655P.
PR 10-JUN-1998; 98US-0088734P.
PR 10-JUN-1998; 98US-0088738P.
PR 10-JUN-1998; 98US-0088742P.
PR 10-JUN-1998; 98US-0088810P.
PR 10-JUN-1998; 98US-0088824P.
PR 10-JUN-1998; 98US-0088826P.
PR 11-JUN-1998; 98US-0088858P.
PR 11-JUN-1998; 98US-0088861P.
PR 11-JUN-1998; 98US-0088876P.

PR	12-JUN-1998;	98US-0089105P.	XX	The present invention relates to the isolation of novel human PRO
PR	16-JUN-1998;	98US-0089440P.	CC	polypeptides, and the polynucleotide sequences encoding them. The PRO
PR	16-JUN-1998;	98US-0089512P.	CC	polypeptides are secreted and transmembrane proteins. The PRO
PR	16-JUN-1998;	98US-0089514P.	CC	polypeptides are useful for detecting other PRO polypeptides, for linking
PR	17-JUN-1998;	98US-0089532P.	CC	bioactive molecules to cells expressing PRO polypeptides, and for
PR	17-JUN-1998;	98US-0089538P.	CC	biological activities of cells expressing PRO polypeptides, and for
PR	17-JUN-1998;	98US-0089598P.	CC	identifying agonists or antagonists. The polynucleotide sequences
PR	17-JUN-1998;	98US-0089599P.	CC	encoding PRO polypeptides are useful as hybridisation probes, in
PR	17-JUN-1998;	98US-0089600P.	CC	chromosome and gene mapping, in the generation of antisense RNA and DNA,
PR	17-JUN-1998;	98US-0089653P.	CC	or knockout animals, to construct hybridisation probes for mapping the
PR	18-JUN-1998;	98US-0089801P.	CC	gene which encodes the PRO polypeptide, and for the genetic analysis of
PR	18-JUN-1998;	98US-0089907P.	CC	individuals with genetic disorders, in gene therapy for chromosome
PR	18-JUN-1998;	98US-0089908P.	CC	identification, as chromosome markers, and for generating probes for PCR,
PR	16-SEP-1998;	98WO-US019330.	CC	Northern analysis, Southern analysis, and Western analysis. The present
PR	17-SEP-1998;	98WO-US019437.	CC	sequence encodes a human PRO polypeptide of the invention. Note: The
PR	07-OCT-1998;	98WO-US021141.	CC	sequence data for this patent was obtained in electronic format directly
PR	01-DEC-1998;	98WO-US025108.	CC	from the USPTO web site at seqdata.uspto.gov/psipsdIDentry.html
PR	05-JAN-1999;	99WO-US000106.	XX	Sequence 1728 BP; 438 A; 360 C; 390 G; 540 T; 0 U; 0 Other;
PR	08-MAR-1999;	99WO-US005028.	XX	Sequence 1728 BP; 438 A; 360 C; 390 G; 540 T; 0 U; 0 Other;
PR	02-JUN-1999;	99WO-US012252.	XX	Sequence 1728 BP; 438 A; 360 C; 390 G; 540 T; 0 U; 0 Other;
PR	15-SEP-1999;	99WO-US021090.	XX	Sequence 1728 BP; 438 A; 360 C; 390 G; 540 T; 0 U; 0 Other;
PR	15-SEP-1999;	99WO-US021547.	XX	Sequence 1728 BP; 438 A; 360 C; 390 G; 540 T; 0 U; 0 Other;
PR	30-NOV-1999;	99WO-US028313.	XX	Sequence 1728 BP; 438 A; 360 C; 390 G; 540 T; 0 U; 0 Other;
PR	01-DEC-1999;	99WO-US028301.	XX	Sequence 1728 BP; 438 A; 360 C; 390 G; 540 T; 0 U; 0 Other;
PR	01-DEC-1999;	99WO-US028634.	XX	Sequence 1728 BP; 438 A; 360 C; 390 G; 540 T; 0 U; 0 Other;
PR	16-DEC-1999;	99WO-US030095.	XX	Sequence 1728 BP; 438 A; 360 C; 390 G; 540 T; 0 U; 0 Other;
PR	20-DEC-1999;	99WO-US030911.	XX	Sequence 1728 BP; 438 A; 360 C; 390 G; 540 T; 0 U; 0 Other;
PR	06-JAN-2000;	2000WO-US000219.	XX	Sequence 1728 BP; 438 A; 360 C; 390 G; 540 T; 0 U; 0 Other;
PR	06-JAN-2000;	2000WO-US000376.	XX	Sequence 1728 BP; 438 A; 360 C; 390 G; 540 T; 0 U; 0 Other;
PR	11-FEB-2000;	2000WO-US003565.	XX	Sequence 1728 BP; 438 A; 360 C; 390 G; 540 T; 0 U; 0 Other;
PR	18-FEB-2000;	2000WO-US004341.	XX	Sequence 1728 BP; 438 A; 360 C; 390 G; 540 T; 0 U; 0 Other;
PR	23-FEB-2000;	2000WO-US004414.	XX	Sequence 1728 BP; 438 A; 360 C; 390 G; 540 T; 0 U; 0 Other;
PR	24-FEB-2000;	2000WO-US004914.	XX	Sequence 1728 BP; 438 A; 360 C; 390 G; 540 T; 0 U; 0 Other;
PR	24-FEB-2000;	2000WO-US005004.	XX	Sequence 1728 BP; 438 A; 360 C; 390 G; 540 T; 0 U; 0 Other;
PR	02-MAR-2000;	2000WO-US005841.	XX	Sequence 1728 BP; 438 A; 360 C; 390 G; 540 T; 0 U; 0 Other;
PR	10-MAR-2000;	2000WO-US006319.	XX	Sequence 1728 BP; 438 A; 360 C; 390 G; 540 T; 0 U; 0 Other;
PR	15-MAR-2000;	2000WO-US006884.	XX	Sequence 1728 BP; 438 A; 360 C; 390 G; 540 T; 0 U; 0 Other;
PR	20-MAR-2000;	2000WO-US007377.	XX	Sequence 1728 BP; 438 A; 360 C; 390 G; 540 T; 0 U; 0 Other;
PR	30-MAR-2000;	2000WO-US008439.	XX	Sequence 1728 BP; 438 A; 360 C; 390 G; 540 T; 0 U; 0 Other;
PR	15-MAY-2000;	2000WO-US013358.	XX	Sequence 1728 BP; 438 A; 360 C; 390 G; 540 T; 0 U; 0 Other;
PR	17-MAY-2000;	2000WO-US013705.	XX	Sequence 1728 BP; 438 A; 360 C; 390 G; 540 T; 0 U; 0 Other;
PR	22-MAY-2000;	2000WO-US014042.	XX	Sequence 1728 BP; 438 A; 360 C; 390 G; 540 T; 0 U; 0 Other;
PR	30-MAY-2000;	2000WO-US014941.	XX	Sequence 1728 BP; 438 A; 360 C; 390 G; 540 T; 0 U; 0 Other;
PR	02-JUN-2000;	2000WO-US015264.	XX	Sequence 1728 BP; 438 A; 360 C; 390 G; 540 T; 0 U; 0 Other;
PR	28-JUL-2000;	2000WO-US020710.	XX	Sequence 1728 BP; 438 A; 360 C; 390 G; 540 T; 0 U; 0 Other;
PR	11-AUG-2000;	2000WO-US022031.	XX	Sequence 1728 BP; 438 A; 360 C; 390 G; 540 T; 0 U; 0 Other;
PR	23-AUG-2000;	2000WO-US023522.	XX	Sequence 1728 BP; 438 A; 360 C; 390 G; 540 T; 0 U; 0 Other;
PR	24-AUG-2000;	2000WO-US023528.	XX	Sequence 1728 BP; 438 A; 360 C; 390 G; 540 T; 0 U; 0 Other;
PR	08-NOV-2000;	2000WO-US030952.	XX	Sequence 1728 BP; 438 A; 360 C; 390 G; 540 T; 0 U; 0 Other;
PR	01-DEC-2000;	2000WO-US032678.	XX	Sequence 1728 BP; 438 A; 360 C; 390 G; 540 T; 0 U; 0 Other;
PR	28-FEB-2001;	2001WO-US006520.	XX	Sequence 1728 BP; 438 A; 360 C; 390 G; 540 T; 0 U; 0 Other;
PR	01-JUN-2001;	2001WO-US017800.	XX	Sequence 1728 BP; 438 A; 360 C; 390 G; 540 T; 0 U; 0 Other;
PR	20-JUN-2001;	2001WO-US019692.	XX	Sequence 1728 BP; 438 A; 360 C; 390 G; 540 T; 0 U; 0 Other;
PR	29-JUN-2001;	2001WO-US021066.	XX	Sequence 1728 BP; 438 A; 360 C; 390 G; 540 T; 0 U; 0 Other;
PR	09-JUL-2001;	2001WO-US021735.	XX	Sequence 1728 BP; 438 A; 360 C; 390 G; 540 T; 0 U; 0 Other;
PR	28-AUG-2001;	2001US-00941992.	XX	Sequence 1728 BP; 438 A; 360 C; 390 G; 540 T; 0 U; 0 Other;
PA	(GETH) GENENTECH INC.		XX	
PA	Ashkenazi AJ, Baker KP, Botstein D, Desnoyers L, Eaton DL;		XX	
PI	Ferrara N, Fong S, Gerber H, Gerritsen ME, Goddard A, Godowski PJ;		XX	
PI	Grimaldi JC, Gurney AL, Kljavin LJ, Napier MA, Pan J, Paoni NF;		XX	
PI	Roy MA, Stewart TA, Tumas D, Watanabe CK, Williams PM, Wood WI;		XX	
PI	Zhang Z;		XX	
XX	WPI; 2003-340824/32.		XX	
DR	P-PSDB; ABO26022.		XX	
DR			XX	
XX	Novel isolated PRO polypeptides e.g., PRO826, PRO1068, PRO1184, PRO1346		XX	
PT	and PRO1375, which stimulate proliferation of stimulated T-lymphocytes		XX	
PT	and are therapeutically useful for enhancing immune responses.		XX	
XX	Claim 2; Fig 299; 661pp; English.		XX	
PS			XX	

Db 901 AAAGTCAGGCAATAAGTCTTTTCCTATTTGTGACTTTTACTAATAAAAAATAAATCTGCCT 960
QY 961 GTAAATTAATCTTGAAGTCTTTTACCTGGAACAAGCACTCTCTTTTTCACCATAGTTTTT 1020
Db 961 GTAAATTAATCTTGAAGTCTTTTACCTGGAACAAGCACTCTCTTTTTCACCATAGTTTTT 1020
QY 1021 AACTTGACCTTCAAGATAATTTTCAGGGTTTTTGTGTTTTTGTGTTTTTGTGTTTTTGTG 1080
Db 1021 AACTTGACCTTCAAGATAATTTTCAGGGTTTTTGTGTTTTTGTGTTTTTGTGTTTTTGTG 1080
QY 1081 TTGCTGGAGAGGGGAGGATGCTGGGAAGTGGTTAAACAATTTTTCAGTCACTTTA 1140
Db 1081 TTGCTGGAGAGGGGAGGATGCTGGGAAGTGGTTAAACAATTTTTCAGTCACTTTA 1140
QY 1141 CTAACAACAATTTTGTAAATAGACCTTACCTCTAATTTTCGAGTTTCATTTATATTTCG 1200
Db 1141 CTAACAACAATTTTGTAAATAGACCTTACCTCTAATTTTCGAGTTTCATTTATATTTCG 1200
QY 1201 AGTGTAGCCAGCCTCATCAAGAGCTGACTTACTCATTTTGACTTTTGCACTGACGTATT 1260
Db 1201 AGTGTAGCCAGCCTCATCAAGAGCTGACTTACTCATTTTGACTTTTGCACTGACGTATT 1260
QY 1261 ATCTGGGTATCTGCTGTCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 1320
Db 1261 ATCTGGGTATCTGCTGTCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 1320
QY 1321 TTTCACAAAAGCAGATTTTCTCATGTACTGTGATGCTGATGCTGATGCTGATGCTGATGCT 1380
Db 1321 TTTCACAAAAGCAGATTTTCTCATGTACTGTGATGCTGATGCTGATGCTGATGCTGATGCT 1380
QY 1381 AAACCTGCCATTGTCTAGTTTACTCTAAAGACTAAACATAGTCTTTGGTGTGTGTGTCTT 1440
Db 1381 AAACCTGCCATTGTCTAGTTTACTCTAAAGACTAAACATAGTCTTTGGTGTGTGTGTCTT 1440
QY 1441 ACTCATCTTCTAGTACCTTTAGGACAATCTTAGGACTTGGACACTTGGACACTTGCATAAGAA 1500
Db 1441 ACTCATCTTCTAGTACCTTTAGGACAATCTTAGGACTTGGACACTTGGACACTTGCATAAGAA 1500
QY 1501 ATTTTATTTTAAACCCCAAGCCTCCCTGGATTGATATATATACATTTGTGCACTTTC 1560
Db 1501 ATTTTATTTTAAACCCCAAGCCTCCCTGGATTGATATATATACATTTGTGCACTTTC 1560
QY 1561 CGGTGCTGTGTGAGGAGCTGTTTGTAGCTCCAATATGTGCACTTTGAACTAGGGCTGG 1620
Db 1561 CGGTGCTGTGTGAGGAGCTGTTTGTAGCTCCAATATGTGCACTTTGAACTAGGGCTGG 1620
QY 1621 GGTGTGGGTGCTCTTCTGAAAGCTTAACCATTTTGGATAACTGGCTTTTCTTCC 1680
Db 1621 GGTGTGGGTGCTCTTCTGAAAGCTTAACCATTTTGGATAACTGGCTTTTCTTCC 1680
QY 1681 TATGCTCTTTTGGATGTAAACAATAAAAAATTTTGAACATCAA 1728
Db 1681 TATGCTCTTTTGGATGTAAACAATAAAAAATTTTGAACATCAA 1728

Search completed: April 20, 2004, 04:01:45
Job time : 699 secs

GenCore version 5.1.6
Copyright (c) 1993 - 2004 Compugen Ltd.

OM nucleic - nucleic search, using sw model

Run on: April 20, 2004, 01:58:41 ; Search time 6718 Seconds
(without alignments)
11148.670 Million cell updates/sec

Title: US-09-989-725-417
Perfect score: 1728
Sequence: 1 cagcgggtcccaagcgtgt.....aataattttgaaacatcaa 1728

Scoring table: IDENTITY_NUC
Gapop 10.0 , Gapext 1.0

Searched: 3470272 seqs, 21671516995 residues

Total number of hits satisfying chosen parameters: 6940544

Minimum DB seq length: 0
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database : GenEmbl:*
1: gb.ba:*
2: gb.htg:*
3: gb.in:*
4: gb.om:*
5: gb.ov:*
6: gb.pat:*
7: gb.ph:*
8: gb.pl:*
9: gb.pr:*
10: gb.ro:*
11: gb.sts:*
12: gb.sy:*
13: gb.un:*
14: gb.vi:*
15: em.ba:*
16: em.fun:*
17: em.hum:*
18: em.in:*
19: em.mu:*
20: em.om:*
21: em.or:*
22: em.ov:*
23: em.pat:*
24: em.ph:*
25: em.pl:*
26: em.ro:*
27: em.sts:*
28: em.un:*
29: em.vi:*
30: em.htg.hum:*
31: em.htg.inv:*
32: em.htg.other:*
33: em.htg.mus:*
34: em.htg.pln:*
35: em.htg.rod:*
36: em.htg.nam:*
37: em.htg.vrt:*
38: em.sv:*
39: em.htgo.hum:*
40: em.htgo.mus:*
41: em.htgo.other:*

Pred. No. is the number of results predicted by chance to have a

score greater than or equal to the score of the result being printed,
and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB	ID	Description
1	1728	100.0	1728	6	AR252653	AR252653 Sequence
2	1728	100.0	1728	6	AX055468	AX055468 Sequence
3	1728	100.0	1728	6	AX055716	AX055716 Sequence
4	1728	100.0	1728	6	AX077037	AX077037 Sequence
5	1728	100.0	1728	6	AX403530	AX403530 Sequence
6	1728	100.0	1728	9	AY359069	AY359069 Homo sapi
7	1630.4	97.8	1772	9	BC040124	BC040124 Homo sapi
8	1685.4	97.5	1834	6	BD222662	BD222662 Human sig
9	1672.2	96.8	1694	6	BD127721	BD127721 Primer fo
10	1672.2	96.8	1694	9	AR074677	AR074677 Homo sapi
11	1649.2	95.4	1734	6	AR352701	AR352701 Sequence
12	1649.2	95.4	1734	6	BD195646	BD195646 70 human
13	1589.6	92.0	1772	6	AR352639	AR352639 Sequence
14	1589.6	92.0	1772	6	BD195584	BD195584 70 human
15	1589.6	92.0	1772	6	BD218614	BD218614 71 human
16	1514.8	87.7	1669	9	BC015884	BC015884 Homo sapi
17	1498	86.7	1498	6	BD170617	BD170617 NF-kappa
18	1498	86.7	1498	9	AB097017	AB097017 Homo sapi
19	1494.4	86.5	1500	6	BD233471	BD233471 Human pro
20	1402.2	81.1	1626	6	BD218547	BD218547 71 human
21	1183.4	68.5	224761	9	AC026894	AC026894 Homo sapi
22	1181.8	68.4	256164	9	HSR400877	AJ400877 Homo sapi
23	1159.4	67.1	160849	2	AC011219	AC011219 Homo sapi
24	1159.4	67.1	163126	9	AC124658	AC124658 Homo sapi
25	974.8	56.4	209573	2	AC100761	AC100761 Homo sapi
26	903.8	52.3	1720	6	BD269862	BD269862 The poly
27	901.4	52.2	1686	10	BC002208	BC002208 Mus muscu
28	594	34.4	594	6	BD233461	BD233461 Human pro
29	584	33.8	589	6	BD124761	BD124761 Primer fo
30	584	33.8	589	6	BD126776	BD126776 Primer fo
31	532.8	30.8	231883	2	AC132584	AC132584 Mus muscu
32	532.8	30.8	234169	10	MMU400878	AJ400878 Mus muscu
33	502	29.1	502	6	AX397151	AX397151 Sequence
34	502	29.1	502	6	AX397171	AX397171 Sequence
35	376.6	21.8	61820	2	AC120026	AC120026 Homo sapi
36	337.4	19.5	339	11	G38653	G38653 SHGC-64039
37	312.2	18.1	1054	5	BC050159	BC050159 Danio rer
38	280.6	16.2	437	11	G21187	G21187 human STS W
39	279.4	16.2	207364	2	AC120564	AC120564 Rattus no
40	279.4	16.2	266766	2	AC094770	AC094770 Rattus no
41	257.6	14.9	61820	2	AC120026	AC120026 Homo sapi
42	208	12.0	70553	2	AC120030	AC120030 Homo sapi
43	202.6	11.7	1562	6	BD170687	BD170687 NF-kappa
44	196.8	11.4	1499	6	AX136089	AX136089 Sequence
45	196.8	11.4	1499	6	BD093294	BD093294 Amyloid b

ALIGNMENTS

RESULT 1
AR252653
LOCUS AR252653 1728 bp DNA linear PAT 20-DEC-2002
DEFINITION Sequence 417 from patent US 6478825.
ACCESSION AR252653
VERSION AR252653.1 GI:27300561
KEYWORDS Unknown.
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 1728)
AUTHORS Winterbottom,J.M., Shimp,L., Boyce,T.M. and Kaes,D.
TITLE Implant, method of making same and use of the implant for the treatment of bone defects
JOURNAL Patent: US 6478825-A 417 12-NOV-2002;

FEATURES		Location/Qualifiers	
Source	1..1728	/organism="Homo sapiens"	
		/mol_type="unassigned DNA"	
		/db_xref="taxon:9606"	
ORIGIN			
Query Match	100.0%;	Score 1728;	DB 6; Length 1728;
Best Local Similarity	100.0%;	Pred. No. 0;	
Matches 1728;	Conservative 0;	Mismatches 0;	Indels 0; Gaps 0;
QY	1	CAGCGGGTCCCAAGCCTGTGCTGAGCCTGAGCCTGAGCCTGAGCCCGAGCGGAGCC	60
Db	1	CAGCGGGTCCCAAGCCTGTGCTGAGCCTGAGCCTGAGCCTGAGCCCGAGCGGAGCC	60
QY	61	GCTGGCGGGGCTCCGGGCTGTGGAGCGCTGGGCCCCAGCGATGGCGACCTGTGGGG	120
Db	61	GCTGGCGGGGCTCCGGGCTGTGGAGCGCTGTGGAGCGCTGGGCCCCAGCGATGGCGACCTGTGGGG	120
QY	121	AGGCTTCTTCGGCTTGGCTCTTCTGCTCAGCCTGTGCTGCTGCTGCTGCTGCTGCT	180
Db	121	AGGCTTCTTCGGCTTGGCTCTTCTGCTCAGCCTGTGCTGCTGCTGCTGCTGCTGCT	180
QY	181	GCTGGCGGAGCTGTGAGCGCGCCAGGAATTCGAGGATGTCAGATGAATGATCTG	240
Db	181	GCTGGCGGAGCTGTGAGCGCGCCAGGAATTCGAGGATGTCAGATGAATGATCTG	240
QY	241	CCCTCCCTATAAGAAATTCCTGGCATATTTAATAAGAACATATCTCAGAAGATTG	300
Db	241	CCCTCCCTATAAGAAATTCCTGGCATATTTAATAAGAACATATCTCAGAAGATTG	300
QY	301	TGATTCCTTCTGTTGGAGCCCATGCTGTGGGGGCTGATGATGAGCATACTG	360
Db	301	TGATTCCTTCTGTTGGAGCCCATGCTGTGGGGGCTGATGATGAGCATACTG	360
QY	361	TCTACGCTGTGAATGAAATATGAGAAAGAGCTCTGTCAAAATCAAGGTTACCATAT	420
Db	361	TCTACGCTGTGAATGAAATATGAGAAAGAGCTCTGTCAAAATCAAGGTTACCATAT	420
QY	421	AATTTATCTCTCAATTTGGGCTTCTACTCTGTACATGTTATATCTTACTCTGGTTGA	480
Db	421	AATTTATCTCTCAATTTGGGCTTCTACTCTGTACATGTTATATCTTACTCTGGTTGA	480
QY	481	GCCCATCTGAGAGCGGCTCTTTGGACATGACAGTTGATGATGATGATGAT	540
Db	481	GCCCATCTGAGAGCGGCTCTTTGGACATGACAGTTGATGATGATGATGAT	540
QY	541	TGGGATCACAGCCTTTTGCATATGCACAGATGTGCTAGCCGCTCCCGAGTCGAGC	600
Db	541	TGGGATCACAGCCTTTTGCATATGCACAGATGTGCTAGCCGCTCCCGAGTCGAGC	600
QY	601	CAACGCTGACAGGTAGATATGACAGAGCGCTGGAAGCTTCAAGTCCAGAGCA	660
Db	601	CAACGCTGACAGGTAGATATGACAGAGCGCTGGAAGCTTCAAGTCCAGAGCA	660
QY	661	GCAGAGTCTGCTTTGACCGGCTGTTGCTCTCAGCTAATTTGGGAATGGAATCAAGGT	720
Db	661	GCAGAGTCTGCTTTGACCGGCTGTTGCTCTCAGCTAATTTGGGAATGGAATCAAGGT	720
QY	721	GACTAGAAAGAACAGGACAGCAACTGGAAAGCACTGAGTGGTGGTGGTGGTGGT	780
Db	721	GACTAGAAAGAACAGGACAGCAACTGGAAAGCACTGAGTGGTGGTGGTGGTGGT	780
QY	781	TTAATACCTTGTGATTTCACCAACTGTTGCTGGAAGATTCAAACTGGAAGCAAAACT	840
Db	781	TTAATACCTTGTGATTTCACCAACTGTTGCTGGAAGATTCAAACTGGAAGCAAAACT	840
QY	841	TGCTGATTTTTTTTCTGTTAACTAATAATAGAGACATTTTAAAGACACAGCTC	900
Db	841	TGCTGATTTTTTTTCTGTTAACTAATAATAGAGACATTTTAAAGACACACAGCTC	900
QY	901	AAAGTCAGCAATAAGTCTTTTCTTCTTCTTCTTCTTCTTCTTCTTCTTCTTCTTCT	960

Db	901	AAAGTCAGCAATAAGTCTTTTCTTCTTCTTCTTCTTCTTCTTCTTCTTCTTCTTCT	960
QY	961	GTAAATATCTTGAAGTCTTTTACCTGGAAACAAGCACTCTCTTTTCCACACATAGTTT	1020
Db	961	GTAAATATCTTGAAGTCTTTTACCTGGAAACAAGCACTCTCTTTTCCACACATAGTTT	1020
QY	1021	AACTTGACTTTCAAGATAAATTTTTCAGGGTTTTTCTGTTGTTGTTGTTGTTGTTGTT	1080
Db	1021	AACTTGACTTTCAAGATAAATTTTTCAGGGTTTTTCTGTTGTTGTTGTTGTTGTTGTT	1080
QY	1081	TTGGTGGAGAGGGAGGATGCTCTGGGAAGTGTGTTAAACACTTTTTCAGTCCACITTA	1140
Db	1081	TTGGTGGAGAGGGAGGATGCTCTGGGAAGTGTGTTAAACACTTTTTCAGTCCACITTA	1140
QY	1141	CTAAACAAACATTTTGTAAATAGACCTTACCTCTTATTTTCGAGTTTCAATATATTTC	1200
Db	1141	CTAAACAAACATTTTGTAAATAGACCTTACCTCTTATTTTCGAGTTTCAATATATTTC	1200
QY	1201	AGTGTAGCAGCCTCATCAAGAGCTGACTTACTTCTTCTTCTTCTTCTTCTTCTTCT	1260
Db	1201	AGTGTAGCAGCCTCATCAAGAGCTGACTTACTTCTTCTTCTTCTTCTTCTTCTTCT	1260
QY	1261	ATCTGGGTATCTGCTGTCTGCTGCTTCAATGTAACCGGATCTAAATATGCTTGGTGGCT	1320
Db	1261	ATCTGGGTATCTGCTGTCTGCTGCTTCAATGTAACCGGATCTAAATATGCTTGGTGGCT	1320
QY	1321	TTTTCACAAAAAGCAGATTTTCTTCTGATGCTGATGCTGATGCTGATGCTGATGCTG	1380
Db	1321	TTTTCACAAAAAGCAGATTTTCTTCTGATGCTGATGCTGATGCTGATGCTGATGCTG	1380
QY	1381	AAACTGGCCATTTGCTAGTTTACTTCTTAAAGACTTAAACATAGTCTTGGTGTGCTGCTT	1440
Db	1381	AAACTGGCCATTTGCTAGTTTACTTCTTAAAGACTTAAACATAGTCTTGGTGTGCTGCTT	1440
QY	1441	ACTCATCTTCTAGTACCTTTAAGGACAAATCTTAAAGACTTGGACACTTGCATTAAGA	1500
Db	1441	ACTCATCTTCTAGTACCTTTAAGGACAAATCTTAAAGACTTGGACACTTGCATTAAGA	1500
QY	1501	ATTTTATTTTAAACCCAGCCTCCCTGGATTGATAATATATACATTTTCTGAGCATTTTC	1560
Db	1501	ATTTTATTTTAAACCCAGCCTCCCTGGATTGATAATATATACATTTTCTGAGCATTTTC	1560
QY	1561	CGGTGCTGCTGAGAGCAGCTGTTTGGCTTCAATATGTCAGCTTGAACCTAGGGCTGG	1620
Db	1561	CGGTGCTGCTGAGAGCAGCTGTTTGGCTTCAATATGTCAGCTTGAACCTAGGGCTGG	1620
QY	1621	GGTGTGGGCTGCTTCTGAAAGGCTTAAACATTTATGGAATACTGCTTTTCTTCTTC	1680
Db	1621	GGTGTGGGCTGCTTCTGAAAGGCTTAAACATTTATGGAATACTGCTTTTCTTCTTC	1680
QY	1681	TATGTCTCTTTTGGATGTAAACATAAATAAATTTTGAACATCAA 1728	
Db	1681	TATGTCTCTTTTGGATGTAAACATAAATAAATTTTGAACATCAA 1728	

RESULT 3	AX055716	1728 bp	DNA	linear	PAT 13-JAN-2001
LOCUS	Sequence 31 from Patent WO0073348.				
DEFINITION	AX055716				
ACCESSION	AX055716.1	GI:12228841			
VERSION					
KEYWORDS	Homo sapiens (human)				
SOURCE	Homo sapiens				
ORGANISM	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;				
	Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.				
REFERENCE					
AUTHORS	Baker, K.P., Goddard, A., Gurney, A.L., Hebert, C., Henzel, W.,				
	Kabakoff, R.C., Shelton, D.L., Smith, V., Watanabe, C.K. and Wood, W.I.				
TITLE	Methods and compositions for inhibiting neoplastic cell growth				
JOURNAL	Patent: WO 0073348-A 31 07-DEC-2000;				
	Genentech, Inc. (US)				
FEATURES	Location/Qualifiers				

[illegible]

Db	401	TGAAATGCAAAATATGAAGAAAGAGCTCTGTGCAAAATCAAGGTTATACATTTATATTTATCT	460
Qy	430	CTCCATTTTGGGCCCTTCTACTTTCTGTATCATGGTATATCTTACTCTGTGGTTGAGCCCATACT	489
Db	461	CTCCATTTTGGGCCCTTCTACTTTCTGTATCATGGTATATCTTACTCTGTGGTTGAGCCCATACT	520
Qy	490	GAAGAGGGCGCTCTTTGGACATGACACAGTTGTATACACAGAGTGATGATATTTGGGGATCA	549
Db	521	GAAGAGGGCGCTCTTTGGACATGACACAGTTGTATACACAGAGTGATGATATTTGGGGATCA	580
Qy	550	CCAGCCTTTTGCAAATGACACAGATGTCTAGCCGCTCCCGAGTCGAGCGCAACGTGCT	609
Db	581	CCAGCCTTTTGCAAATGACACAGATGTCTAGCCGCTCCCGAGTCGAGCGCAACGTGCT	640
Qy	610	GAACAAGGTGAGAAATATGACACAGACGCGCTGGAAGCTTCAAGTCCAGAGACGACGAAAGTC	669
Db	641	GAACAAGGTGAGAAATATGACACAGACGCGCTGGAAGCTTCAAGTCCAGAGACGACGAAAGTC	700
Qy	670	TGCTCTTTGACCGGCAATGTGTCTCAGCTAATTGGGAAATTGAATTCAGAGTGACTAGAAA	729
Db	701	TGCTCTTTGACCGGCAATGTGTCTCAGCTAATTGGGAAATTGAATTCAGAGTGACTAGAAA	760
Qy	730	GAACAAGACACACACTGGGAAGAACTGACTGGGTTTTCCTGGGTTTCAATTTTAATACCT	789
Db	761	GAACAAGGACACAACTGGGAAGAACTGACTGGGTTTTCCTGGGTTTCAATTTTAATACCT	820
Qy	790	TGCTCAATTCACCAACTGTGTCTGGGAAGATCAAAACTGGAAAGCAAAACTTGCTTGAT	849
Db	821	TGCTCAATTCACCAACTGTGTCTGGGAAGATCAAAACTGGAAAGCAAAACTTGCTTGAT	880
Qy	850	TTTTTTTTCTGTTAACGTTAAATAATAGAGACATTTTTTAAAGACACACAGCTCAAGATCAGC	909
Db	881	TTTTTTTTCTGTTAACGTTAAATAATAGAGACATTTTTTAAAGACACACAGCTCAAGATCAGC	940
Qy	910	CAATTAAGTCCTTTTCCCTATTTGTGACTTTTACTAATAAAATAAATCTGCGCTGTAAATAT	969
Db	941	CAATTAAGTCCTTTTCCCTATTTGTGACTTTTACTAATAAAATAAATCTGCGCTGTAAATAT	1000
Qy	970	CTTTGAAGTCCTTTTACTCTGGAAACAGCACTCTCTTTTTTCCACCATAGTTTTTAACCTGACT	1029
Db	1001	CTTTGAAGTCCTTTTACTCTGGAAACAGCACTCTCTTTTTTCCACCATAGTTTTTAACCTGACT	1060
Qy	1030	TTCAAGATAAATTTTCAGGGTTTTTGTGTGTTTGTGTTTTTGTGTTTTTGTGTTGGTGGA	1089
Db	1061	TTCAAGATAAATTTTCAGGGTTTTTGTGTGTTTGTGTTTTTGTGTTTTTGTGTTGGTGGA	1120
Qy	1090	GAGGGAGGGGATGCCTGGGAAGTGGTTAACAACTTTTTTCAAGTCACTTTACTTAAACAAA	1149
Db	1121	GAGGGAGGGGATGCCTGGGAAGTGGTTAACAACTTTTTTCAAGTCACTTTACTTAAACAAA	1180
Qy	1150	CTTTTGTAAATAGACCTTACCTCTATTTTTCGAGTTTCAATTTATATTTTTCGAGTGATGCC	1209
Db	1181	CTTTTGTAAATAGACCTTACCTCTATTTTTCGAGTTTCAATTTATATTTTTCGAGTGATGCC	1240
Qy	1210	AGCCTCATCAAGAGCTGACTTACTCATTTTGACTTTTTTGCACTGACTGTATATCTGGGTA	1269
Db	1241	AGCCTCATCAAGAGCTGACTTACTCATTTTGACTTTTTTGCACTGACTGTATATCTGGGTA	1300
Qy	1270	TCTGCTGTGTGCACTTCATGGTAAACGGGATCTAAATATGCTGGTGGCTTTTTCACAAA	1329
Db	1301	TCTGCTGTGTGCACTTCATGGTAAACGGGATCTAAATATGCTGGTGGCTTTTTCACAAA	1360
Qy	1330	AAGCAGATTTTCTTCATGTACTGTGATGTCTGATGCAATGCATCTCTAGAAACAAACTGGCC	1389
Db	1361	AAGCAGATTTTCTTCATGTACTGTGATGTCTGATGCAATGCATCTCTAGAAACAAACTGGCC	1420
Qy	1390	ATTTGCTAGTTTACTCTTAAGACTTAAACATAGTCTTTGGTGTGTGGTCTTACTCATCTT	1449
Db	1421	ATTTGCTAGTTTACTCTTAAGACTTAAACATAGTCTTTGGTGTGTGGTCTTACTCATCTT	1480
Qy	1450	CTAGTACCTTTTAAAGACAAATTCCTTAAGGACTTGGACACTTGGCAATTAAGAAATTTTATTT	1509

Db 1481 CTAGTACTCTTTAAGGACAAATCCTTAAGGACTTGGACACTTGGCAATAAAGAAATTTTATTT 1544
 Qy 1510 TAAACCCAAAGCCTCCCTGGATTGATAATATATATACATTTGTCCAGCATTTCCCGTCTGG 1569
 Db 1541 TAAACCCAAAGCCTCCCTGGATTGATAATATATATACATTTGTCCAGCATTTCCCGTCTGG 1600
 Qy 1570 TGAGAGCAGCTGTTTTCAGCTCCAAATATATGTCAGCTTTGAACTAGGCTGGGGTTGTGGG 1629
 Db 1601 TGAGAGCAGCTGTTTTCAGCTCCAAATATGTCAGCTTTGAACTAGGCTGGGGTTGTGGG 1660
 Qy 1630 TGCCTCTCTGAAAGGCTTAACCATTTATGGAATAACTGGCTTTTCTTCTTATGTCCTC 1689
 Db 1661 TGCCTCTCTGAAAGGCTTAACCATTTATGGAATAACTGGCTTTTCTTCTTATGTCCTC 1713
 Qy 1690 TTTGGAATGTAAACAATAAATAATTTTGAACAATCAA 1728
 Db 1714 TTGGAATGTAAACAATAAATAATTTTGAACAATCAA 1752

 RESULT 9
 BD127721
 LOCUS
 DEFINITION 1694 bp DNA linear PAT 18-SEP-2002
 ACESSION
 VERSION
 KEYWORDS
 SOURCE
 ORGANISM
 Homo sapiens
 Homo sapiens (human)
 BD127721
 BD127721
 BD127721
 JP 2002017375-A/3152
 Homo sapiens (human)
 Homo sapiens
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
 Ota, T., Nishikawa, T., Isegai, T., Havaashi, K., Ishii, S., Kawai, Y.,
 Wakamatsu, A., Sugiyama, T., Nagai, K., Kojima, S., Otsuki, T. and
 Kaga, H.
 Primer for synthesizing full-length cDNA and use thereof
 Patent: JP 2002017375-A 3152 22-JAN-2002;
 HELIX RESEARCH INSTITUTE
 OS Homo sapiens (human)
 PN JP 2002017375-A/3152
 PD 22-JAN-2002
 PF 07-JUL-2000 JP 2000253172
 PI TOSHIO OTA, TETSUO NISHIKAWA, TAKAO ISOGAI, KOJI HAYASHI, SHIZUKO
 PI ISHII,
 PI YURI KAWAI, AI WAKAMATSU, TOMOYASU SUGIYAMA, KEIICHI NAGAI, PI
 SHINICHI KOJIMA,
 PI TETSUJI OTSUKI, HISASHI KOGA
 PC
 C12N15/09, C07K14/47, C07K16/18, C12N1/15, C12N1/19, C12N1/21, C12N5/ PC
 10,
 PC, C12P21/02, C12Q1/68, C12P21/08, G06F17/30, C12N15/00, C12N5/00 CC
 Primer for synthesizing full-length cDNA and use thereof FH Key
 Location/Qualifiers
 FT CDS
 (79).. (672).
 Location/Qualifiers
 1. .1694
 /organism="Homo sapiens"
 /mol_type="genomic DNA"
 /db_xref="taxon:9606"

 FEATURES
 source

 ORIGIN

 Query Match 96.8%; Score 1672.2; DB 6; Length 1694;
 Best Local Similarity 99.4%; Pred. No. 0;
 Matches 1691; Conservative 0; Mismatches 3; Indels 7; Gaps 1;

 Qy 26 AGCCTGAGCCTGAGCCTGAGCCGAGCCGGAGCCGGTCCGGGGGCTCCGGGCTGTGGG 85
 Db 1 AGCCTGAGCCTGAGCCTGAGCCGAGCCGGAGCCGGTCCGGGGGCTCCGGGCTGTGGG 60

 Qy 86 AC CGCTGGGCCCCAGCGATGGGACCCCTGTGGGAGGCCCTTCTCGGCTTGGCTCCTTG 145
 Db 61 AC CGCTGGGCCCCAGCGATGGGACCCCTGTGGGAGGCCCTTCTCGGCTTGGCTCCTTG 120

 Qy 146 CTAGCCTGTGCTGCTCGGCGCTTTCGCTGCTGCTGCTGCGCAGCTGTGAGACGCCGCC 205

<div style="float: right; width: 100px;">/clone="MAMMA1001344"</div>					
<div style="float: right; width: 100px;">/tissue_type="mammary gland"</div>					
<div style="float: right; width: 100px;">/clone_lib="MAMMA1"</div>					
<div style="float: right; width: 100px;">/note="cloning vector: pME18SFL3"</div>					
<div style="float: right; width: 100px;">79..675</div>					
<div style="float: right; width: 100px;">/note="unnamed protein product"</div>					
<div style="float: right; width: 100px;">/codon_start=1</div>					
<div style="float: right; width: 100px;">/protein_id="BAC11131.1"</div>					
<div style="float: right; width: 100px;">/db_xref="GI:22760274"</div>					
<div style="float: right; width: 100px;">/translation="NATLWGGLLRLRGSLSLSIALSVLLLAQLSDAAKNFEDVRKVC ICPPYKNSGTHYNKIISQDCDLHVPFPDVEAYIEACECKEIBERSVITIK VTIIIVSLIGTILLYMYLVLTIVPEILKRRIFGHAQLIOSDDDIGHQPFANAHVILA RRSRANVLNKVEYAQRWLKVQBRKSVDPRHVLS"</div>					
<div style="clear: both;"></div>					
ORIGIN					
Query Match 96.8%; Score 1672.2; DB 9; Length 1694;					
Best Local Similarity 99.4%; Pred. No. 0; Mismatches 3; Indels 7; Gaps 1;					
Matches 1691; Conservative 0;					
QY	26	AGCCTGAGCGCTGAGCGTGAGCCGAGCGGAGCGCGGTGCGGGGGCTCCGGGCTGTGGG	85		
DB	1	AGCCTGAGCGCTGAGCGTGAGCCGAGCGGAGCGCGGTGCGGGGGCTGTGGG	60		
QY	86	ACCCTGGGCCCCAGCGATGGCACCTGTGGGAGGCCTTCCTGGCTTTGGCTCTTG	145		
DB	61	ACCCTGGGCCCCAGCGATGGCACCTGTGGGAGGCCTTCCTGGCTTTGGCTCTTG	120		
QY	146	CTCAGCGCTGCTGCGTGGCGCTTTCCGTCGCTGCTGGCGCAGCTGTCAAGCGCGCC	205		
DB	121	CTCAGCGCTGCTGCGTGGCGCTTTCCGTCGCTGCTGGCGCAGCTGTCAAGCGCGCC	180		
QY	206	AAGAAATTCGAGATGTCAAGTGAATCTATCTGCCTCCCTATAAAGAAAATCTGGG	265		
DB	181	AAGAAATTCGAGATGTCAAGTGAATCTATCTGCCTCCCTATAAAGAAAATCTGGG	240		
QY	266	CATATTATAAAGAACAATATCTCAGAAAGATGTGATTTGCTTCATGTTGTGAGGCC	325		
DB	241	CATATTATAAAGAACAATATCTCAGAAAGATGTGATTTGCTTCATGTTGTGAGGCC	300		
QY	326	ATGCTGTGGGGGCTGATGTAGAACATCTCTACGCTGTGAATGCAGAAATGAA	385		
DB	301	ATGCTGTGGGGGCTGATGTAGAACATCTCTACGCTGTGAATGCAGAAATGAA	360		
QY	386	GAAAGAGCTCTGTCAAAATCAAGGTACCATTATAATTATCTCTCCATTTTGGGCTT	445		
DB	361	GAAAGAGCTCTGTCAAAATCAAGGTACCATTATAATTATCTCTCCATTTTGGGCTT	420		
QY	446	CTACTTCTGACATGGTATATCTTACTCTGGTTGAGCCCATCTAGAGGGGCTCTTT	505		
DB	421	CTACTTCTGACATGGTATATCTTACTCTGGTTGAGCCCATCTAGAGGGGCTCTTT	480		
QY	506	GGCATGCACAGTTGATACAGATGTATGATATTGGGGATCACCAGCTTTTCCAAT	565		
DB	481	GGCATGCACAGTTGATACAGATGTATGATATTGGGGATCACCAGCTTTTCCAAT	540		
QY	566	GCACAGATGTAGCCGCTCCGAGTCGAGCCAGCTGCTGACAGAGTAGAATAT	625		
DB	541	GCACAGATGTAGCCGCTCCGAGTCGAGCCAGCTGCTGACAGAGTAGAATAT	600		
QY	626	GCACAGAGCGCTGGAGCTTCAAGTCCAGAGAGCAGGAAAGTCTGTCTTTCACCGCAT	685		
DB	601	GCACAGAGCGCTGGAGCTTCAAGTCCAGAGAGCAGGAAAGTCTGTCTTTCACCGCAT	660		
QY	686	GTGTCTCTCAGCTAATTTGGAAATGTAATCAAGGTGACTAGAAAGAAACAGCAGCAAC	745		
DB	661	GTGTCTCTCAGCTAATTTGGAAATGTAATCAAGGTGACTAGAAAGAAACAGCAGCAAC	720		
QY	746	TGGAAGAACTGACTGGGTTTTCGCTGGTTTCAATTTAATCTGTTGATTTCCACCAAC	805		
DB	721	TGGAAGAACTGACTGGGTTTTCGCTGGTTTCAATTTAATCTGTTGATTTCCACCAAC	780		
QY	806	TGTTGCTGGAGATTCAGAACTGGAGCAAAAGTCTGTTGATTTTTTTCTTGTAAAC	865		

REFERENCE 1 (bases 1 to 1734)
AUTHORS Ruben, S.M., Rosen, C.A., Fischer, C.L., Soppet, D.R., Carter, K.C.,
Bednarek, D.P., Endress, G.A., Yu, G.-L., Ni, J., Feng, P., Young, P.E.,
Greene, J.M., Ferrer, A.M., Duan, R., Hu, J.-S., Florence, K.A.,
Olson, H.S., Ebner, R., Brewer, L.A. and Shi, Y.
TITLE Secreted protein HODAZ50
JOURNAL Patent: US 6590075-A 108 08-JUL-2003;
FEATURES Location/Qualifiers
1..1734
/organism="unknown"
/mol_type="genomic DNA"

ORIGIN
Query Match 95.4%; Score 1649.2; DB 6; Length 1734;
Best Local Similarity 99.1%; Pred. No. 0;
Matches 1712; Conservative 0; Mismatches 4; Indels 11; Gaps 5;
5 CGGGTCCCAAGCCTGTGGCTGAGCTGAGCTGAGCCTGAGCCGAGCGCGAGCGGTC 64
1 CGGGTCCCAAGCCTGTGGCTGAGCTGAGCCTGAGCCTGAGCCGAGCGCGAGCGGTC 60
65 GCGGGGGTCCCGGCTGTGGACCGCTGGGCCCGCCAGCGATGGCGACCCCTGTGGGAGGC 124
61 GCGGGGGTCCCGGCTGTGGACCGCTGGGCCCGCCAGCGATGGCGACCCCTGTGGGAGGC 120
125 CTTCTTGGCTGGCTCCTTGTCTGACCTGTGCTGCTGCTGGCGCTTCGGTCTGCTGCTG 184
121 CTTCTTGGCTGGCTCCTTGTCTGACCTGTGCTGCTGGCGCTTCGGTCTGCTGCTG 180
185 GCGGAGCTGTGAGCGCGCCCAAGAAATTCGAGGATGTGAGATGAAATGATCTGCGCCT 244
181 GCGGATGT-NCAGACGCGCCCAAGAAATTCGAGGATGTGAGATGAAATGATCTGCGCCT 239
245 CCTATAAGAAATTCCTGGGCATATTTATATAAGAAACATATCTCGAAGAGATTGTGAT 304
240 CCTATAAGAAATTCCTGGGCATATTTATATAAGAAACATATCTCGAAGAGATTGTGAT 299
305 TGCCTTCATGTTGGAGCCCATGCTGTGCGGGCCCTGATGAGAGCATCTGCTA 364
300 TGCCTTCATGTTGGAGCCCATGCTGTGCGGGCCCTGATGAGAGCATCTGCTA 359
365 CGCTGTGAATGCAATATGAAGAAAGAGCTGTGCACAAATCAAGGTTACCAATTAAT 424
360 CGCTGTGAATGCAATATGAAGAAAGAGCTGTGCACAAATCAAGGTTACCAATTAAT 419
425 TATCTCTCCATTTTGGGCTTCTACTCTGACATGATGATATCTTACTCTGCTGAGGCC 484
420 TATCTCTCCATTTTGGGCTTCTACTCTGACATGATGATATCTTACTCTGCTGAGGCC 479
485 ATACTGAAGAGGCGCTCTTTGGACATGACACAGTTGATACAGAGTGATGATATGGG 544
480 ATACTGAAGAGGCGCTCTTTGGACATGACACAGTTGATACAGAGTGATGATATGGG 539
545 GATCAGCAGCTTTTGAATGACACAGATGCTAGCCGCTCCGCGAGTCGAGCCAC 604
540 GATCAGCAGCTTTTGAATGACACAGATGCTAGCCGCTCCGCGAGTCGAGCCAC 599
605 GTCTGAACAAGGTAGATATGACACAGCAGCTGGAAGCTTCAAGTCCACAGAGCAGA 664
600 GTCTGAACAAGGTAGATATGACACAGCAGCTGGAAGCTTCAAGTCCACAGAGCAGA 659
665 AAGTCTGTCTTTCACCGGCAATGTTCTCAGCTAATTTGGGAATTTCAAGGTGAC 723
660 AAGTCTGTCTTTCACCGGCAATGTTCTCAGCTAATTTGGGAATTTCAAGGTGAC 719
724 TAGAAGACAGCAGCAGCAACT-GGAAGAACTGACTGGG-TTTTGGCTGGGTTTCATTT 781
720 TAGAAGACAGCAGCAGCAACTGGAAGAACTGACTGGG-TTTTGGCTGGGTTTCATTT 779
782 TAATACCTTGTGATTTTCACTTCCAACTGTGCTGGAAGATTCAAACTGGAAGCAAACTT 841
780 TAATACCTTGTGATTTTCACTTCCAACTGTGCTGGAAGATTCAAACTGGAAGCAAACTT 839

842 GCTTGATTTTTTTTCTTCTTAACTAATAGAGACATTTTAAAGCACACAGCTCA 901
840 GCTTGATTTTTTTTCTTCTTAACTAATAGAGACATTTTAAAGCACACAGCTCA 899
902 AAGTCAGCAATAAGTCCTTTTCTTAACTAATAGAGACATTTTAAAGCACACAGCTCA 961
900 AAGTCAGCAATAAGTCCTTTTCTTAACTAATAGAGACATTTTAAAGCACACAGCTCA 959
962 TAAATATCTTGAAGTCCTTTTCTTAACTAATAGAGACATTTTAAAGCACACAGCTCA 1021
960 TAAATATCTTGAAGTCCTTTTCTTAACTAATAGAGACATTTTAAAGCACACAGCTCA 1019
1022 ACTTGACTTTCAAGATAAATTTTCAAGGTTTTTGTGTTGTTGTTGTTGTTGTTT 1081
1020 ACTTGACTTTCAAGATAAATTTTCAAGGTTTTTGTGTTGTTGTTGTTGTTGTTT 1079
1082 TGGTGGAGAGGGAGGGATGCTGGGAAGTGGTTAAACAATTTTCAAGTCACATTAC 1141
1080 TGGTGGAGAGGGAGGGATGCTGGGAAGTGGTTAAACAATTTTCAAGTCACATTAC 1139
1142 TAAACAACAATTTTGAATAAGACCTTACCTTCTATTTTCAAGTTTCAATTTATTTTGA 1201
1140 TAAACAACAATTTTGAATAAGACCTTACCTTCTATTTTCAAGTTTCAATTTATTTTGA 1199
1202 GTGTAGCAGCCCTCATCAAGAGAGCTGACTTACTTCAATTTGACTTTTGCACATGATTA 1261
1200 GTGTAGCAGCCCTCATCAAGAGAGCTGACTTACTTCAATTTGACTTTTGCACATGATTA 1259
1262 TCTGGGTATCTGCTGTGCTGCACTTCAATGTTAAAGGGATCTAAAGTCTGCTGGCTT 1321
1260 TCTGGGTATCTGCTGTGCTGCACTTCAATGTTAAAGGGATCTAAAGTCTGCTGGCTT 1319
1322 TTCAAAAAAGCAGATTTTCTTCAATGCTGCTGATGCTGATGCAATGCAATCTAGAAC 1381
1320 TTCAAAAAAGCAGATTTTCTTCAATGCTGCTGATGCTGATGCAATGCAATCTAGAAC 1379
1382 AACTGGCCATTTGCTAGTTTACTCTAAAGACTAAACATAGTCTGCTGCTGCTGCTTA 1441
1380 AACTGGCCATTTGCTAGTTTACTCTAAAGACTAAACATAGTCTGCTGCTGCTGCTTA 1439
1442 CTCACTTCTAGTACCTTTTAAAGCAAACTCCTAAGGACTTGGACACTTGAATTAAGAAA 1501
1440 CTCACTTCTAGTACCTTTTAAAGCAAACTCCTAAGGACTTGGACACTTGAATTAAGAAA 1499
1502 TTTTATTTTAAACCCAGCCTCCTGGATTTGATTAATATACATTTTGCAGCATTTCC 1561
1500 TTTTATTTTAAACCCAGCCTCCTGGATTTGATTAATATACATTTTGCAGCATTTCC 1559
1562 GGTGCTGTGAGAGGAGCTGTTTGAAGTCCCAATATGTCAGCTTTTGAATAGGCTGGG 1621
1560 GGTGCTGTGAGAGGAGCTGTTTGAAGTCCCAATATGTCAGCTTTTGAATAGGCTGGG 1619
1622 GTTGTGGGTGCTCTTCTGAAAGCTTAAACATTTATTTGATTAATGCTTTTCTTCT 1681
1620 GTTGTGGGTGCTCTTCTGAAAGCTTAAACATTTATTTGATTAATGCTTTTCTTCT 1675
1682 ATGTCTCTTTTGGATGATTAACATAAATAATTTTGAACATCAA 1728
1676 ---TCCTCTTTTGAATGATAAATAAATAATTTTGAACATCAA 1719

RESULT 12
BD195646
LOCUS BD195646 70 human secreted proteins.
DEFINITION
ACCESSION BD195646
VERSION BD195646.1 GI:33005416
KEYWORDS JP 2002519990-A/107.
SOURCE unidentified
ORGANISM unidentified
REFERENCE 1 (bases 1 to 1734)
AUTHORS Ruben, S.M., Rosen, C.A., Fischer, C.L., Soppet, D.R., Carter, K.C.,

QY	896	AGCTCAAGTCAGCCAAATAGCTTTTCTATTTGTCATTTTAACTATAAAATAAATC	955
DB	925	AGCTCAAGTCAGCCAAATAGCTTTTCTATTTGTCATTTTAACTATAAAATAAATC	984
QY	956	TGCTGTAAATATCTT--GAAGTCCTTTACCTGGAACAAGCACTCTTTTTCACCA	1013
DB	985	TGCTGTAAATATCTTAAATAATCTTTACCTGGAACAAGCACTCTTTTTCACCA	1044
QY	1014	TAGTTTAACTGACTTT--CAAGATAATTTTTCAGGGTTTGTGTTGTTGTTTGT	1072
DB	1045	TAGTTTAACTGACTTTTCCAGATAATTTTTCAGGGTTTGTGTTGTTGTTTGT	1104
QY	1073	TGTTTGTGTTGAGAGGAGGAGGATCCCTGGGAAGTGGTTTAACTTTTTCAG	1132
DB	1105	TGTTTGTGTTGAGAGGAGGAGGATCCCTGGGAAGTGGTTTAACTTTTTCAG	1164
QY	1133	TCACCTTACTAAACAACCTTTGTAATAAGACTTACCTTCTATTTTCGAGTTTCA	1192
DB	1165	TCACCTTACTAAACAACCTTTGTAATAAGACTTACCTTCTATTTTCGAGTTTCA	1224
QY	1193	TATTTGTCAGTGTAGCCAGCTCATCAAGAGCTGACTTACTCATTTGACCTTTG	1252
DB	1225	TATTTGTCAGTGTAGCCAGCTCATCAAGAGCTGACTTACTCATTTGACCTTTG	1284
QY	1253	ACTGTATTTCTGGGTATCTGCTGTCTGCACTTCAAGTAAACGGATCTAAATGCC	1312
DB	1285	ACTGTATTTCTGGGTATCTGCTGTCTGCACTTCAAGTAAACGGATCTAAATGCC	1344
QY	1313	TGTTGCTTTTTCACAAAAAGCAGATTTTCTTCATGTCATGTCATGTCATGTCAT	1372
DB	1345	TGTTGCTTTTTCACAAAAAGCAGATTTTCTTCATGTCATGTCATGTCATGTCAT	1404
QY	1373	CTAGAACAACTGGGCTATCTGCTGTCTGCACTTCAAGTAAACGGATCTAAATGCC	1432
DB	1405	CTAGAACAACTGGGCTATCTGCTGTCTGCACTTCAAGTAAACGGATCTAAATGCC	1464
QY	1433	GTGGTCTTACTCATCTCTAGTACCTTTAAGGACAACTCTAAGGACCTTGGACCTG	1492
DB	1465	GTGGTCTTACTCATCTCTAGTACCTTTAAGGACAACTCTAAGGACCTTGGACCTG	1524
QY	1493	ATAAGAAATTTTATTTTAAACCAAGCTCCCTGATGATGATGATGATGATGATG	1552
DB	1525	ATAAGAAATTTTATTTTAAACCAAGCTCCCTGATGATGATGATGATGATGATG	1584
QY	1553	AGCATTTCCGGTCTGCTGAGAGGAGCTGTTTGACCTCAATATGTCAGCTTTGA	1612
DB	1585	AGCATTTCCGGTCTGCTGAGAGGAGCTGTTTGACCTCAATATGTCAGCTTTGA	1644
QY	1613	AGGCTGGGTTGTGGTGTCTTCTGAAAGCTTAAACATTTTGGATTAAGCTTT	1672
DB	1645	AGGCTGGGTTGTGGTGTCTTCTGAAAGCTTAAACATTTTGGATTAAGCTTT	1704
QY	1673	TTTCTTCTATGCTCTTTGGATGTAACAATAAAATAATTTTGAACATCAA	1728
DB	1705	TTTCT-----TCTCTTTGGATGTAACAATAAAATAATTTTGAACATCAA	1754

RESULT 14
BD195584
LOCUS
DEFINITION 70 human secreted proteins.
ACCESSION BD195584
VERSION BD195584.1 GI:33005354
KEYWORDS JP 2002519990-A/45.
SOURCE unidentified
ORGANISM unclassified.
REFERENCE 1 (bases 1 to 1772)
Bednarik,D.P., Endress,G.A., Yu,G.L., N.J., Feng,P., Young,P.E.,
Greene,J.M., Ferrer,A.M., Duan,R., Hu,J.S., Florence,K.A.,
Olsen,H.S., Ebner,R., Brewer,L.A., Moore,P.A., Shi,Y.,

Lafleur,D.W., Li,Y., Zeng,Z. and Kyaw,H.
70 human secreted proteins
Patent: JP 2002519990-A 45 02-JUL-2002;
HUMAN GENOME SCIENCES INC
OS Unidentified
PN JP 2002519990-A/45
PD 02-JUL-2002
PF 06-MAR-1997 US 1998538875 60/040162,07-MAR-1997 US 60/040333 PR
PR 07-MAR-1997 US 60/038621,07-MAR-1997 US 60/040161 PR
07-MAR-1997 US 60/040626,07-MAR-1997 US 60/040334 PR
07-MAR-1997 US 60/040336,07-MAR-1997 US 60/040163 PR
11-APR-1997 US 60/043580,11-APR-1997 US 60/043568 PR
11-APR-1997 US 60/043314,11-APR-1997 US 60/043569 PR
11-APR-1997 US 60/043311,11-APR-1997 US 60/043671 PR
11-APR-1997 US 60/043674,11-APR-1997 US 60/043669 PR
11-APR-1997 US 60/043312,11-APR-1997 US 60/043313 PR
11-APR-1997 US 60/043672,11-APR-1997 US 60/043576 PR
11-APR-1997 US 60/043578,11-APR-1997 US 60/047600 PR
11-APR-1997 US 60/043670,23-MAY-1997 US 60/047597 PR
23-MAY-1997 US 60/047615,23-MAY-1997 US 60/047597 PR
23-MAY-1997 US 60/047502,23-MAY-1997 US 60/047633 PR
23-MAY-1997 US 60/047583,23-MAY-1997 US 60/047617 PR
23-MAY-1997 US 60/047618,23-MAY-1997 US 60/047503 PR
23-MAY-1997 US 60/047592,23-MAY-1997 US 60/047581 PR
23-MAY-1997 US 60/047584,23-MAY-1997 US 60/047500 PR
23-MAY-1997 US 60/047587,23-MAY-1997 US 60/047492 PR
23-MAY-1997 US 60/047598,23-MAY-1997 US 60/047613 PR
23-MAY-1997 US 60/047582,23-MAY-1997 US 60/047596 PR
23-MAY-1997 US 60/047612,23-MAY-1997 US 60/047632 PR
23-MAY-1997 US 60/047601,23-MAY-1997 US 60/047595 PR
23-MAY-1997 US 60/047599,23-MAY-1997 US 60/047588 PR
23-MAY-1997 US 60/047585,23-MAY-1997 US 60/047586 PR
23-MAY-1997 US 60/047590,23-MAY-1997 US 60/047594 PR
23-MAY-1997 US 60/047591,23-MAY-1997 US 60/047593 PR
06-JUN-1997 US 60/048974,06-JUN-1997 US 60/048964 PR
22-AUG-1997 US 60/056886,22-AUG-1997 US 60/056877 PR
22-AUG-1997 US 60/056890,22-AUG-1997 US 60/056893 PR
22-AUG-1997 US 60/056892,22-AUG-1997 US 60/056878 PR
22-AUG-1997 US 60/056891,22-AUG-1997 US 60/056872 PR
22-AUG-1997 US 60/056893,22-AUG-1997 US 60/056888 PR
22-AUG-1997 US 60/056879,22-AUG-1997 US 60/056880 PR
22-AUG-1997 US 60/056894,22-AUG-1997 US 60/056911 PR
22-AUG-1997 US 60/056896,22-AUG-1997 US 60/056874 PR
22-AUG-1997 US 60/056910,22-AUG-1997 US 60/056864 PR
22-AUG-1997 US 60/056912,22-AUG-1997 US 60/056845 PR
22-AUG-1997 US 60/056913,22-AUG-1997 US 60/056832 PR
22-AUG-1997 US 60/056864,22-AUG-1997 US 60/056876 PR
22-AUG-1997 US 60/056881,22-AUG-1997 US 60/056909 PR
22-AUG-1997 US 60/056875,22-AUG-1997 US 60/056862 PR
22-AUG-1997 US 60/056887,22-AUG-1997 US 60/056908 PR
22-AUG-1997 US 60/056884,05-SEP-1997 US 60/057761 PR
05-SEP-1997 US 60/057650
PI STEVEN M RUBEN, CRAIG A ROSEN, CARRIE L FISCHER, DANIEL R SOPPET,
PI KENNETH C CARTER, DANIEL P BEDNARIK, GREGORY
A ENDRESS, GUO LIANG
PI YU, JIAN NI
PI FENG FENG, PAUL E YOUNG, JOHN M GREENE, ANN
M FERRIE, ROXANNE DUAN,
PI JING SHAN HU, KIMBERLY A FLORENCE, HENRIK
S OLSEN, REINHARD EBNER,
PI LAURIE A BREWER, PAUL A MOORE, YANGGU SHI, DAVID W LAFLEUR PI
YI LI, ZHIZHEN ZENG,
PI HLA KYAN
PI C12N15/12, C12N5/10, C12N1/21, C07K14/47, C07K16/18, C13Q1/68, PC
GOIN33/50,
PC GOIN33/53, GOIN33/68, A61K38/17
CC Strandedness: Double;
CC Topology: Linear;
CC 70 human secreted proteins
PH Key Location/Qualifiers

Db 1645 AGGGCTGGGGTTGTGGTGCCCTTTCTGAAAGTCTAACCATTTATTGGATAACTGGCTTT 1704
QY 1673 TTTCTTCTATGTCCTCTTTGGAATGTAACAATAAATAATTTTGAACATCAA 1728
Db 1705 TTTTCT-----TCCTCTTTGGAATGTAACAATAAATAATTTTGAACATCAA 1754

Search completed: April 20, 2004, 05:58:36
Job time : 6725 secs

GenCore version 5.1.6
Copyright (c) 1993 - 2004 CompuGen Ltd.

OM nucleic - nucleic search, using sw model

Run on: April 20, 2004, 02:12:11 ; Search time 4580 Seconds
(without alignments)
11266.779 Million cell updates/sec

Title: US-09-989-725-417

Perfect score: 1728
Sequence: 1 cagccgggtcccaagcctgt.....ataattttgaaacatcaa 1728

Scoring table: IDENTITY NUC
Gapop 10.0 , Gapext 1.0

Searched: 27513289 seqs, 14931090276 residues

Total number of hits satisfying chosen parameters: 55026578

Minimum DB seq length: 0
Maximum DB seq length: 2000000000
Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database : EST:*
1: em_estba:*
2: em_esthum:*
3: em_estin:*
4: em_estmu:*
5: em_estov:*
6: em_estpl:*
7: em_estro:*
8: em_htc:*
9: gb_est1:*
10: gb_est2:*
11: gb_htc:*
12: gb_est3:*
13: gb_est4:*
14: gb_est5:*
15: em_estfun:*
16: em_estom:*
17: em_gss_hum:*
18: em_gss_inv:*
19: em_gss_pln:*
20: em_gss_vrt:*
21: em_gss_fun:*
22: em_gss_mam:*
23: em_gss_mus:*
24: em_gss_pro:*
25: em_gss_rod:*
26: em_gss_phg:*
27: em_gss_vrl:*
28: gb_gss1:*
29: gb_gss2:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	947.4	54.8	1045	9	AL542404
2	938	54.3	1180	9	AL575462
3	931.2	53.9	1201	9	AL537331
4	931.2	53.9	1201	13	BX425270

C	5	913.8	52.9	1201	9	AL562476
C	6	904	52.3	1201	13	BX440898
C	7	903.4	52.3	1201	9	AL550557
C	8	899.8	52.1	1642	11	AK077253
C	9	893.8	51.7	1063	12	BM924942
C	10	893.4	51.7	962	9	AL567498
C	11	891.4	51.6	1201	13	BX439642
C	12	890.8	51.6	1201	9	AL552487
C	13	888.6	51.4	1190	9	AL552032
C	14	884	51.2	1201	9	AL576084
C	15	859.2	50.3	953	9	AL540345
C	16	888.4	50.3	1105	12	BM924900
C	17	885.4	50.1	1201	9	AL550588
C	18	854.2	49.4	961	9	AL538778
C	19	851.4	49.3	1020	9	AL543744
C	20	851.4	49.3	1201	13	BX364690
C	21	848.8	49.1	854	9	AL546065
C	22	839.8	48.6	929	13	BX438705
C	23	838.8	48.5	1029	12	BM556889
C	24	826.6	47.8	916	13	BX371884
C	25	826.4	47.8	1772	11	AK049882
C	26	814.4	47.1	900	13	BUI45696
C	27	809	46.8	827	12	BI907871
C	28	806.8	46.7	1194	9	AL575778
C	29	804.6	46.6	962	12	BM921821
C	30	802.2	46.4	950	13	BU552570
C	31	800	46.3	928	13	BU552570
C	32	799.2	46.2	1201	13	BX403296
C	33	787.8	46.2	904	12	BX420531
C	34	789.6	45.7	1201	13	BX397421
C	35	787.2	45.6	1201	13	BX364689
C	36	777.6	45.0	1407	11	AK009147
C	37	765.6	44.3	1201	13	BX425269
C	38	782.6	44.1	911	14	CA454836
C	39	758.4	43.9	1002	9	AL543902
C	40	751.4	43.5	785	12	BI598275
C	41	748.6	43.3	924	13	BX464778
C	42	747	43.2	747	12	BI756642
C	43	731.2	42.3	938	14	CD109149
C	44	724.6	41.9	1121	12	BM918858
C	45	722.8	41.8	879	13	BQ224552

ALIGNMENTS

RESULT 1
AL542404
LOCUS
DEFINITION AL542404 Homo sapiens PLACENTA Homo sapiens cDNA clone CS0DE010YN08
5-PRIME, mRNA sequence.
ACCESSION AL542404
VERSION AL542404.2 GI:30547515
KEYWORDS EST.
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE
1 (Bases 1 to 1045)
Li W.B., Gruber C., Jessee J., and Polayes D.
Full-length cDNA libraries and normalization
Unpublished (2001)
JOURNAL
COMMENT On Feb 15, 2001 this sequence version replaced gi:12874416.
Contact: Genoscope
Genoscope - Centre National de Sequencage
BP 191 91006 EVRY cedex - France
Email: seqref@genoscope.cns.fr, Web : www.genoscope.cns.fr
Library was constructed by Life Technologies, a division of
Invitrogen. This sequence belongs to sequence cluster 6242.f For
more information about this cluster, see
http://www.genoscope.cns.fr/
cgi-bin/cluster.cgi?seq=CS0DE010DG04QPI&cluster=6242.f. Contact :
Feng Liang Email : fliang@lifetech.com URL :

<http://fulllength.invitrogen.com/> InvitroGen Corporation 1600
Faraday Avenue Genoscope sequence ID : CS0DE010DG04QP1.

FEATURES

```

source
location/Qualifiers
1..1045
/organism="Homo sapiens"
/mol_type="mRNA"
/db_xref="taxon:9606"
/clone="CS0E010YN08"
/tissue_type="PLACENTA"
/clone_lib="Homo sapiens PLACENTA"
/notes="vector: pCMVSPORT 6; 1st strand cDNA was primed
with a NotI-oligo(dT) primer. Five prime end enriched,
double-strand cDNA was digested with Not I and cloned into
the Not I and EcoRV sites of the pCMVSPORT 6 vector.
Library was not normalized."

```

ORIGIN

Query Match	54.8%;	Score 947.4;	DB 9;	Length 1045;
Best Local Similarity	95.2%;	Pred. No. 1.6e-169;		
Matches 949;	Conservative 40;	Mismatches 6;	Indels 2;	Gaps 2;

QY	20	TGCTTGAGCCTGAGCGTCAAGCCGACGCCGAGCGGCCTGTCGCGGGSGCTCGGGC	79
Db	50	TTCCCGGATCTGAGSSTGAGCGTAGCSGAGSGGAGSSGTTCGCGGGSTTCGGGC	109
QY	80	TGTGGGACCGCTGGGCCCCCACGATGCGCACCCCTGTGGGGAGCCCTTTCTCGGCTTGC	139
Db	110	TGTGGGACCGCTGGSCSCCCACGATGSGGACCCTGTGGGAGGCGCTTCTTCGGSTTGC	169
QY	140	TGCTTTGCTCAGCCTGCTGCTGCGCGTTTCCTGCTGCTGCTGCTGCGGAGCTGCAGAC	199
Db	170	TGCTTTGCTCAGCCTGCTGCTGCGSCTTTCCTGCTGCTGCTGCTGCGGAG-TGT-SAGAS	228
QY	200	GCGGCCAGAATTTCGAGGATGTCAGATGTAAATGTATCTGCCCTCCCTATAAAGAAAAT	259
Db	229	GSGGCCNAGAATTTSGAGATGTSAGATGTAAATGTATCTGCCCTCCTATAAAGAAAAT	288
QY	260	TCTGGGCATATTTAPATAAGAACATATCTCAGAAAGANTGTGAATGCTTCATGTTGTG	319
Db	289	TCTGGGCATATTTATATAAGAACATATCT-SAGAAAGANTGTGAATGCTTCATGTTGTG	348
QY	320	GAGCCCATGCGCTGCGGGGGCCCTGACTAGAACATCTCTACGCTGTGAATGCAAA	379
Db	349	GAGCSATGCCCTGTGCGGGGGCCCTGATGTAGAGCATCTCTACGSTGTGAATGCAMA	408
QY	380	TATGAAGAAAGAGCTCTGTCACAATCAAGGTTACCAATTATAATTTATCTCTCCAATTTG	439
Db	409	TATGAAGAAAGAGCTCTGT-SACAATCAAGGTTACCAATTATAATTTATCTCTSCAATTTG	468
QY	440	GGCCTTCTACTTCTGTACATGGTATATCTTACTCTGTTGAGGCCCATCTGAAGAGGCGC	499
Db	469	GGCCTTCTACTTCTGTACATGGTATAT-STTACTCTGTTGAGGCCCATCTGAAGAGGCGC	528
QY	500	CTCTTTGGACATGCACAGTTGATACAGAGTGCATCATATTTGGGATCACCAGCCTTTT	559
Db	529	CTCTTTGGACATGCACAGTTGATACAGAGTGCATCATATTTGGGATSNACCAGSCTTTT	588
QY	560	GCAATATGCACAGATGTCTAGCCCGCTCCCGCAGTCGAGCCCAACGTGCTGAACAAGGTA	619
Db	589	GSNAATGCACAGATGTCTAGCCCGCTCCCGCAGTSGAGCCCAACGTGCTGAACAAGGTA	648
QY	620	GAATATGCACRAGCGCTGGAGC-TTCAAGTCCRAGACGCGGAAGTCTGTCTTTGA	678
Db	649	GAATATGCACRAGCGSTGGAGCGTTTCAAGTCCRAGACGCGGAAGTCTGTCTTTGA	708
QY	679	CCGGCATGTGTCTCAGCTAATTTGGGAATTTGAATTTCAAGGTGACTAGAAAAAGAAACAGGC	738
Db	709	CCGGCATGTGTCTCAGCTAATTTGGGAATTTGAATTTCAAGGTGACTAGAAAAAGAAACAGGC	768
QY	739	AGACAACTGGAAAGAACTGACTGGGTTTTGCTGGGTTTCAATTTTAATACCTTGTGATTT	798
Db	769	AGACAACTGGAAAGAACTGACTGGGTTTTGCTGGGTTTCAATTTTAATACCTTGTGATTT	828

Qy	799	CACCAACTGTTGCTGGAAGATTCAAAACTCGGAAGCAAAAACCTTGCCTGATTTTTTTTTCT	859	TTTTTCTATTTGTGACCTTTTACTAAATAAAATAAATCTGCCTGTAAATTATCTTGAAGTC	978
Db	829	CACCAACTGTTGCTGGAAGATTCAAAACTCGGAAGCAAAAACCTTGCCTGATTTTTTTTTTCT	889	TTTTTCTATTTGTGACCTTTTACTAAATAAAATAAATCTGCCTGTAAATKATCTTGAAGTC	1008
Qy	859	TGTTACGTAATAATAGAGACATTTTTTAAAGCACACAGCTCAAAAGTCAGCAATAAAGTC	918	TTTTTCTATTTGTGACCTTTTACTAAATAAAATAAATCTGCCTGTAAATTATCTTGAAGTC	978
Db	889	TGTTACGTAATAATAGAGACATTTTTTAAAGCACACAGCTCAAAAGTCAGCAATAAAGTC	948	TTTTTCTATTTGTGACCTTTTACTAAATAAAATAAATCTGCCTGTAAATKATCTTGAAGTC	1008
Qy	979	CTTTACTGGAAACAAGCACTCTCTTTTTCACGCACATA	1015		
Db	1009	CTTTACTGGGAAGAAGCACTCTCTTTTTCACGCACATA	1045		

RESIT, T 2

RESULT 2	AL575462	1180 bp	linear	EST 01-JUN-2003
LOCUS	AL575462			
DEFINITION	AL575462 Homo sapiens PLACENTA COT 25-NORMALIZED Homo sapiens CDNA clone CSODI060VL12 3-PRIME, mRNA sequence.			
ACCESSION	AL575462			
VERSION	AL575462.2	GI:31313770		
KEYWORDS	EST.			
SOURCE	Homo sapiens (human)			
ORGANISM	Homo sapiens			
	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.			
REFERENCE	1 (bases 1 to 1180)			
AUTHORS	Li, W.B., Gruber, C., Jesse, J. and Polayes, D.			
TITLE	Full-length cDNA libraries and normalization			
JOURNAL	Unpublished (2001)			
COMMENT	On Feb 15, 2001 this sequence version replaced gi:12936648.			

FEATURES

```

FEATURES
    source
    location/qualifiers
    1. 1180
    /organism="Homo sapiens"
    /mol_type="mRNA"
    /db_xref="taxon:9606"
    /clone="CS0D1060Y112"
    /tissue_type="PLACENTA COT 25-NORMALIZED"
    /note="1st strand cDNA was primed with a NotI-oligo (dr)
    primer. Five prime end enriched, double-strand cDNA was
    digested with Not I and cloned into the Not I and EcoR V
    sites of the pCMVSPORT 6 vector. Library was normalized."

```

ORIGIN

	Query Match	54.3%	Score 938;	DB 9;	Length 1180;	
	Best Local Similarity	94.6%;	Pred. No. 9.7e-168;			
	Matches 1004;	Conservative 24;	Mismatches 26;	Indels 7;	Gaps 6	
QY	530	AGCAGCGCTGGAAGCTTCAAGTCCAAAGCAGCAGCGAAAGTCGTGTTTGAACCGGCGATGTTG	689			
DB	1058	ACMSGAGCGTGGARSCTCAAGYCCAAAGCASCAGAAAGTCPTKTC-TTMC CGGCGATGTTG	1000			
QY	690	TCCTCAGCTAATTCGGGAATTGAATTCAGGTGACTAGAAAGAAACAGGCAGACAACCTGGA	749			
DB	999	CCCTCAGCTAATTCGGGWAATTC-ADGTKACTAGAAAGAACAGGCAGACAACCTGGA	941			
QY	750	AAGAACTGACTGGGTTTTGCTGGGTTTTCAATTTTAATACCTTGTTGATTT-CACCAACTGT	808			

Db	940	AAGAACTGAC	TGGGTTT--GCTGGKTTCA	TTTTTAATACCTTGTTGATTTCCACAAC	TGT	883
Qy	809	TGCTGGAGAGAT	TCAAAACTGGAAGCAAA	AAACTTCTCTTGATTTTTTTTCTTGTTAAACGTA	868	
Db	882	TGCTGGAGAGAT	TCAAAACTGGAAGCAAA	AAACTTCTCTTGATTTTTTTTCTTGTTAAACGTA	824	
Qy	869	ATAATACAGACAT	TTTTTAAAGCACACAGCTCA	AAAGTCAGCCATAAGTCTTTTCTTCTATT	928	
Db	823	ATAATACAGACAT	TTTTTAAAGCACACAGCTCA	AAAGTCAGCCATAAGTCTTTTCTTCTATT	764	
Qy	929	TGTGAC	TTTTTACTAATAAAAAATAA	AACTGCGCTGTAATATATCTTGAAGTCCCTTACCTGG	988	
Db	763	TGTGAC	TTTTTACTAATAAAAAATAA	AACTGCGCTGTAATATATCTTGAAGTCCCTTACCTGG	704	
Qy	989	AACAAGCAC	TCTCTTTTCCACCACATAG	TTTTTAACCTTGACCTTCAAGATAATTTTCAGGG	1048	
Db	703	AACAAGCAC	TCTCTTTTCCACCACATAG	TTTTTAACCTTGACCTTCAAGATAATTTTCAGGG	644	
Qy	1049	TTTTTGT	TGTTGTTTTTTTGT	TTGTTGTTTGTGGAGGGGAGGAGTGCCTGGG	1108	
Db	643	TTTTTGT	TGTTGTTTTTTTGT	TTGTTGTTTGTGGAGGGGAGGAGTGCCTGGG	584	
Qy	1109	AAGTGGTTAC	AACTTTTTTCAAGTCACT	TTTACTAACAACATTTTGTAATAAGACCTTA	1168	
Db	583	AAGTGGTTAC	AACTTTTTTCAAGTCACT	TTTACTAACAACATTTTGTAATAAGACCTTA	524	
Qy	1169	CCTTCTAT	TTTCGAGTTTCATTTATA	TTTTTGCAGTGTAGCAGCCTCATCAAAAGAGCTGA	1288	
Db	523	CCTTCTAT	TTTCGAGTTTCATTTATA	TTTTTGCAGTGTAGCAGCCTCATCAAAAGAGCTGA	464	
Qy	1229	CTTACTCAT	TTTGACTTTTGCAC	TGACGTATATCTGGGTATCTGCTGCTGCGCACTTC	1288	
Db	463	CTCACC	CAATTGACTTTTGCAC	TGACGTATCTGGGTATCTGCTGCTGCGCACTTC	404	
Qy	1289	ATGGTAA	ACGGGATCTAAAAATG	CGTGGTCTTTTCAAAAAAGCAGATTTCTTCATGT	1348	
Db	403	ATGGTAA	ACGGGATCTAAAAATG	CGTGGTCTTTTCAAAAAAGCAGATTTCTTCATGT	344	
Qy	1349	ACTGTGAT	GTCTGATGCAATCCAT	CTCTAGAACAACTGGCCATTTGCTAGTTTACTCTAA	1408	
Db	343	ACTGTGAT	GTCTGATGCAATCCAT	CTCTAGAACAACTGGCCATTTGCTAGTTTACTCTAA	284	
Qy	1409	AGACTAA	CACTAGTCTTGGTGTG	TGTGGTCTTACTCATCTTCTAGTACCTTTAAGACAA	1468	
Db	283	AGACTAA	CACTAGTCTTGGTGTG	TGTGGTCTTACTCATCTTCTAGTACCTTTAAGACAA	224	
Qy	1469	ATCCTA	AGGACTTGGACATTTG	CAATAAAGAAATTTATTTTAAACCAAGCCTCCCTGG	1528	
Db	223	ATCCTA	AGGACTTGGACATTTG	CAATAAAGAAATTTATTTTAAACCAAGCCTCCCTGG	164	
Qy	1529	ATTGATA	ATAATATACATTTGT	CAGCATTTCCGGTCTGGTGAGAGGCACTGTTTGAG	1588	
Db	163	ATTGATA	ATAATATACATTTGT	CAGCATTTCCGGTCTGGTGAGAGGCACTGTTTGAG	104	
Qy	1589	CTCCAA	TATGTGAGCTTTGAA	CTRGGCTGGGGTTGGGGTCTTCTCTGAAAGGTCT	1648	
Db	103	CTCCAA	TATGTGAGCTTTGAA	CTRGGCTGGGGTTGGGGTCTTCTCTGAAAGGTCT	44	
Qy	1649	AACCAT	-TATTGGATA	AACTGGCTTTTTTCTTCCTCATGTCTCT	1688	
Db	43	AA	CNTNNNTTGN	TNACTGGCTTTTTTCTTCBCCTKSK	3	

RESULT 3	AL537331	1201 bp	mrna	linear	EST 31-MAY-2003
LOCUS	AL537331				
DEFINITION	AL537331 Homo sapiens FETAL BRAIN Homo sapiens cDNA clone				
	CS0DF02V005 5-PRIME, mRNA sequence.				
ACCESSION	AL537331				
VERSION	AL537331.2	GI:31361954			
KEYWORDS	EST.				
SOURCE	Homo sapiens (human)				

Db	555	CCATAC	TGAAGAGCGCCTCTTTGGACATGCACAGTTGATACAGAGTGATGATGATG	614
Qy	543	GGGATC	CACAGCCCTTTTGCAAAATGCACAGATGTGCTAGCCCGCTCCGCGAGTCAGGCCA	602
Db	615	GGGATC	CACAGCCCTTTTGCAAAATGCACAGATGTGCTAGCCCGCTCCGCGAGTCAGGCCA	674
Qy	603	ACGTGCT	GAAACAAGTAGAATATGCACAGCAGCGCTGGAAGCTTCAGTCCAAAGAGAGC	662
Db	675	ACGTGCT	GAAACAAGTAGAATATGCACAGCAGCGCTGGAAGCTTCAGTCCAAAGAGAGC	734
Qy	663	GAAAGT	CTGTCTTTGACCGCGCATGTGTCCCTCAGCTAATTTGGGAATGAATTTCAAGTGA	722
Db	735	GAAAGT	CTGTCTTTGACCGCGCATGTGTCCCTCAGCTAATTTGGGAATGAATTTCAAGTGA	794
Qy	723	CTAGAGA	AAACAGCAGACAACCTGGAAAGAACTGACTGGGTTTGTGCTGGGTTTCATTTT	782
Db	795	CTAGAGA	AAACAGCAGACAACCTGGAAAGAACTGACTGGGTTTGTGCTGGGTTTCATTTT	854
Qy	783	AATACCT	TGTTGATTTCACCAACTGTGTCTGGAAGATTCAAAACTGGAGACAAAACTTG	842
Db	855	AATACCT	TGTTGATTTCACCAACTGTGTCTGGAAGATTCAAAACTGGAGACAAAACTTG	914
Qy	843	CTTGA	-TTTTTTTTTCTTTAAAGTAATAATAGAGACATTTTAAAGCACACAGCTCA	901
Db	915	CTTGAT	TTTTTTTTTCTTTAAAGTAATAATAGAGACATTTTAAAGCACACAGCTCA	973
Qy	902	AAGTCAG	CCATAAGTCTTTTCTTATTTGTGACATTTTACTAATAAAAAATAATCTGCGTG	961
Db	974	AAGTCAG	CCATAAGTCTTTTCTTATTTGTGACATTTTACTAATAAAAAATAATCTGCGTG	1032
Qy	962	TAAATTAT	CTTGAAGTCTTTTACCTGGAAACAAGCACCTCTCTTTTCCACCATAGTTTAA	1021
Db	1033	TAAATTAT	CTTGAAGTCTTTTACCTGGAAACAAGCACCTCTCTTTTCCACCATAGTTTAA	1087
Qy	1022	ACTTGAC	TTTCAAGATAATTTTACGGTTTTTGTGTTGTTGTTGTTGTTGTTGTTGTTT	1081
Db	1088	MTTGRCT	TTTCAGA---WAWTTTTCAGGGT-----TTGGTGGTGKGTGTTTTTTTTTTT	1139
Qy	1082	TGGTGGG	AGGAGGAGTGCCTGGGAAGTGGTTAAACATTTTTCAGTCACTTT	1139
Db	1140	TGTGGG	AGGGGGGCGCGGAAGGTAAWACTTTTCAKCAVTTCAAMAATTTT	1197
RESULT 4				
LOCUS	BX425270	1201 bp	mRNA	linear EST 15-MAY-2003
DEFINITION	BX425270 Homo sapiens NEUROBLASTOMA Homo sapiens cDNA clone			
	CU0BB007ZAll 5-PRIME, mRNA sequence.			
ACCESSION	BX425270			
VERSION	BX425270.1	GI:30778450		
KEYWORDS	EST.			
SOURCE	Homo sapiens (human)			
ORGANISM	Homo sapiens			
REFERENCE	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;			
AUTHORS	Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.			
TITLE	1. (bases 1 to 1201)			
JOURNAL	Li, W.B., Gruber, C., Jesses, J. and Polayes, D.			
COMMENT	Full-length cDNA libraries and normalization			
	Unpublished (2001)			
	Contact: Genoscope			
	Genoscope - Centre National de Sequencage			
	BP 191 91006 EVRY cedex - France			
	Email: seqref@genoscope.cns.fr, Web : www.genoscope.cns.fr			
	Library was constructed by Life Technologies, a division of			
	Invitrogen. This sequence belongs to sequence cluster 6242.f For			
	more information about this cluster, see			
	http://www.genoscope.cns.fr/			
	cgi-bin/cluster.cgi?seq=CU0BB007ZAllRP1&cluster=6242.f. Contact :			
	Feng Liang Email : fliang@lifetech.com URL :			
	http://fulllength.invitrogen.com/ Invitrogen Corporation 1600			
	Paraday Avenue Genoscope sequence ID : CU0BB007ZAllRP1.			
	Location/Qualifiers			
FEATURES				


```

KEYWORDS EST.
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
REFERENCE Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
AUTHORS Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
TITLE 1 (bases 1 to 1201)
JOURNAL Li, W.B., Gruber, C., Jessee, J. and Polayes, D.
COMMENT Full-length cDNA libraries and normalization
Unpublished (2001)
Contact: Genoscope
Genoscope - Centre National de Sequencage
BP 191 91006 EVRY cedex - France
Email: seqref@genoscope.cns.fr, Web : www.genoscope.cns.fr
Library was constructed by Life Technologies, a division of
Invitrogen. This sequence belongs to sequence cluster 6242.f For
more information about this cluster, see
http://www.genoscope.cns.fr/
cgi-bin/cluster.cgi?seq=CS0DF012BC07QPI&cluster=6242.f. Contact :
Feng Liang Email : fliang@lifetech.com URL :
http://fulllength.invitrogen.com/ Invitrogen Corporation 1600
Faraday Avenue Genoscope sequence ID : CS0DF012BC07QPI.
FEATURES
Location/Qualifiers
1..1201
/organism="Homo sapiens"
/mol_type="mRNA"
/db_xref="taxon:9606"
/clone="CS0DF012YE14"
/tissue_type="FETAL BRAIN"
/dev_stage="fetal"
/clone_lib="Homo sapiens FETAL BRAIN"
/note="Organ: brain, Vector: pCMVSPORT 6; 1st strand cDNA
was primed with a NotI-oligo(dT) primer. Five prime end
enriched, double-strand cDNA was digested with Not I and
cloned into the Not I and EcoRV sites of the pCMVSPORT 6
vector. Library was not normalized."
ORIGIN
Query Match 52.38; Score 904; DB 13; Length 1201;
Best Local Similarity 93.8; Pred. No. 2.7e-161;
Matches 951; Conservative 20; Mismatches 36; Indels 7; Gaps 3;
Qy 113 CTGTGGGGAGGCGCTTCTCGGCTGGCTCTTGTCTGCTGAGCGCTGTCGTCGCTGGCGCTTTC 172
Db 61 CTGTGGGGAGGCGCTTCTCGGCTGGCTCTTGTCTGCTGAGCGCTGTCGTCGCTGGCGCTTTC 120
Qy 173 GTGCTGCTGTGGGCGAGCTGTGAGCGCGCGCCAGAAATTCGAGGATGTCAGATGTA 232
Db 121 GTGCTGCTGTGGGCGCA-STGTGAGCGCGCCCAAGAAATTCGAGGATGTCAGATGTA 179
Qy 233 TGTATCTGCTCCCTCTAAGAAATTCGCGGCATATTTAATAAGACATATCTCAG 292
Db 180 TGTATCTGCTCCCTCTAAGAAATTCGCGGCATATTTAATAAGACATATCTCAG 239
Qy 293 AAAGATTGTGATTCGCTCTATGTTGTGGAGCCCATGCTGTGGGGGCGCTGATGTAGAA 352
Db 240 AAAGATTGTGATTCGCTCTATGTTGTGGAGCCCATGCTGTGGGGGCGCTGATGTAGAA 299
Qy 353 GCATCTGCTACCGCTGGAATCAATATGAGAAAGAGCTGTGCACATCAAGGTT 412
Db 300 GCATCTGCTACCGCTGGAATCAATATGAGAAAGAGCTGTGCACATCAAGGTT 359
Qy 413 ACCATTATAATTTATCTCTCAATTTGGGCGCTTCTACTTCTGACATGGTATATCTACT 472
Db 360 ACCATTATAATTTATCTCTCAATTTGGGCGCTTCTACTTCTGACATGGTATATCTACT 419
Qy 473 CTGCTTGAGCCCATCTGAGAGGCGCTCTTTGGACATGCACAGTTGTACAGATGAT 532
Db 420 CTGCTTGAGCCCATCTGAGAGGCGCTCTTTGGACATGCACAGTTGTACAGATGAT 479
Qy 533 GATGATATTTGGGATCACCAGCTTTTGCAAATGCACACAGATGTGCTAGCCGCTCCCGC 592
Db 480 GATGATATTTGGGATCACCAGCTTTTGCAAATGCACACAGATGTGCTAGCCGCTCCCGC 539

```

```

Qy 593 AGTCAGCCCAACGTGCTGAACAAGGTAGATATGCACAGCAGCGCTCGAAGCTTCAAGTC 652
Db 540 AGTCAGCCCAACGTGCTGAACAAGGTAGATATGCACAGCAGCGCTCGAAGCTTCAAGTC 599
Qy 653 CAAGAGCAGCGAAGTCTGCTTTGACCGGCGATGTTGCTCTCAGCTAATTTGGGAATTGAA 712
Db 600 CAAGAGCAGCGAAGTCTGCTTTGACCGGCGATGTTGCTCTCAGCTAATTTGGGAATTGAA 659
Qy 713 TTCAAGGTGACTAGAAAGAAACAGGCGAGACAACCTGGAAGAACTGACTGGGTTTGTCTGG 772
Db 660 TTCAAGGTGACTAGAAAGAAACAGGCGAGACAACCTGGAAGAACTGACTGGGTTTGTCTGG 719
Qy 773 GTTTCATTTTAATACCTTGTGATTTCACCACTGTTGCTGGAAGATTCAAAACCTGGAAG 832
Db 720 GTTTCATTTTAATACCTTGTGATTTCACCACTGTTGCTGGAAGATTCAAAACCTGGAAG 779
Qy 833 CAAAACCTGCTGCTGATTTTTTTCTTGTAACTAATATAGAGACATTTTTTAAAGCA 892
Db 780 CAAAACCTGCTGCTGATTTTTTTCTTGTAACTAATATAGAGACATTTTTTAAAGCA 839
Qy 893 CACAGCTCAAAAGTCAGCAATTAAGTCTTTTCTTATTTGTGACTTTTACTATAAAATAA 952
Db 840 CACAGCTCAAAAGTCAGCAATTAAGTCTTTTCTTATTTGTGACTTTTACTATAAAATAA 899
Qy 953 ATCTGCTGTAAATTAATCTTGAAGTCTTTTACCTGGAACAGCACTCTTTTTTCAACCAC 1012
Db 900 ATCTGCTGTAAATTAATCTTGAAGTCTTTTACCTGGAACAGCACTCTTTTTTCAACCAC 959
Qy 1013 ATAGTTTTTAACCTTGACTTTTCAAGATAATTTTCAGGTTTGTGTTGTTTGTGTTT 1072
Db 960 ATAGTTTTTACGTTGGGKCAAGATAATTTTCAGGTTGTTGTTGTTGTTGTTGTTGTT 1018
Qy 1073 TGTGTTTGTGTTGGGAGAGGAGGATGCTGCTGGAGTGTGTTTAAACAACATTTT 1126
Db 1019 GGGTTTTT-----TGGBSMRGGGGRGGGAKSCYKGRAGKGGTWMAMKTTTTT 1067
RESULT 7
AL550557/c 1201 bp mRNA linear EST 31-MAY-2003
LOCUS AL550557 Homo sapiens PLACENTA COT 25-NORMALIZED Homo sapiens cDNA
DEFINITION clone CS0DI058YJ16 3-PRIME, mRNA sequence.
ACCESSION AL550557
VERSION AL550557.2 GI:31272374
KEYWORDS EST.
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1 (bases 1 to 1201)
AUTHORS Li, W.B., Gruber, C., Jessee, J. and Polayes, D.
TITLE Full-length cDNA libraries and normalization
JOURNAL Unpublished (2001)
COMMENT On Feb 15, 2001 this sequence version replaced gi:12887637.
Contact: Genoscope
Genoscope - Centre National de Sequencage
BP 191 91006 EVRY cedex - France
Email: seqref@genoscope.cns.fr, Web : www.genoscope.cns.fr
Library was constructed by Life Technologies, a division of
Invitrogen. This sequence belongs to sequence cluster 6173.r
Contact: Feng Liang Email : fliang@lifetech.com URL :
http://fulllength.invitrogen.com/ Invitrogen Corporation 1600
Faraday Avenue Genoscope sequence ID : CS0DI058DE08NFI.
FEATURES
Location/Qualifiers
1..1201
/organism="Homo sapiens"
/mol_type="mRNA"
/db_xref="taxon:9606"
/clone="CS0DI058YJ16"
/tissue_type="PLACENTA COT 25-NORMALIZED"
/clone_lib="Homo sapiens PLACENTA COT 25-NORMALIZED"
/note="1st strand cDNA was primed with a NotI-oligo(dT)
primer. Five prime end enriched, double-strand cDNA was

```


RIKEN Yokohama Institute; 1-7-22 Suehiro-cho, Tsurumi-ku, Yokohama,
Kanagawa 230-0045, Japan (E-mail: genome-res@gsr.riken.go.jp,
URL: http://genome.gsc.riken.go.jp/, Tel: 81-45-503-9222,
Fax: 81-45-503-9216)

COMMENT
cDNA library was prepared and sequenced in Mouse Genome
Encyclopedia Project of Genome Exploration Research Group in Riken
Genomic Sciences Center and Genome Science Laboratory in RIKEN.
Division of Experimental Animal Research in Riken contributed to
prepare mouse tissues.
Please visit our web site for further details.
URL: http://genome.gsc.riken.go.jp/
URL: http://fantom.gsc.riken.go.jp/
Location/Qualifiers

FEATURES

source

```

1..1642
    /organism="Mus musculus"
    /mol_type="mRNA"
    /strain="C57BL/6J"
    /db_xref="FANTOM_DB:5031426103"
    /db_xref="MGI:2393085"
    /db_xref="taxon:10090"
    /clone="5031426103"
    /sex="female"
    /tissue_type="ovary and uterus"
    /clone_lib="RIKEN full-length enriched mouse cDNA library"
    /dev_stage="11 days pregnant adult"
42..541
    /note="unnamed protein product; Clorf15 PROTEIN homolog  
[Homo sapiens] (SPTXQ9NQ34, evidence: FASTV, 94.5%ID,  
100%length, match=597)  
putative"
    /codon_start=1
    /protein_id="BAC36710.1"
    /db_xref="GI:26346118"
    /translation="MNSLWCGNLRGLSGLSMCLASVLLALQLTGAARNFEDVRCK  
CTCPYKNPQHIYKNSIQKDCDCLHVEPMVPGPDVEAYCLRCCKVEERSVVI  
KVIIILSLIGLLLVYVLTLPVEILKRLFGHSOLLQSDDDVDGHPANAHDL  
APSRERANLVKVEVAQQRWKLQVQERKSFDRHVLS"
    polyA_signal
1620..1625
    /note="putative"
1642
    /note="putative"

```

ORIGIN

```

Query Match          52.1%; Score 899.8; DB 11; Length 1642;
Best Local Similarity 77.9%; Pred. No. 1.6e-160;
Matches 1300; Conservative 0; Mismatches 322; Indels 47; Gaps 16;

QY 68 GGGGCTCGGGCTGTGGACCGCTGGGCCCGCCAGCGCATGGGACCGCT--GTGGGGAGGC 124
DB 6 GGGGCTCGGGCTCGCAGAGCGGCTGGCTCCCGGATGGCGAGCGCTATGGTGGGAAAC 65

QY 125 CTTCTCGGCTGGCTTGTCTGCTGACCGCTGCTGCTGGCGCTTCGCTGCTGCTGCTG 184
DB 66 CTGCTCGGCTGGGCTCGGGGCTCAGCATGTCTCGCTGGCGCTCGGCTGCTGCTGCTC 125

QY 185 GCGGAGCTGACAGCGCCCGCCAGAAATTTTCGAGGATGTGAGATGTAATGATCTGCGCCT 244
DB 126 GCGGAGCTGACAGCGCGCCCGCCAGAAATTTTGAAGATGTGAGATGTAATGATCTGCGCCT 185

QY 245 CCTATAAGAAATTTCTGGGATATTTATATATAGACATATCTCAGAAAGATTGTGAT 304
DB 186 CCTATAAGAAATTTCTGGGACATTTTATATAAGAAATATATCTCAGAAAGATTGTGAT 245

QY 305 TGCCTTCATGTTGTGAGCGCCATGCTGTGGGGGCGCTGTGATGAGAGCATCTGTCTA 364
DB 246 TGCCTTCATGTTGTGAGCGCCATGCTGTACGGGACCTGTGATGAGAGCATCTGTCTA 305

QY 365 CGCTGTGAATGCAATATATGAAAGAGAGCTCTGTGACATCAATCAAGGTTACATTAAT 424
DB 306 CGCTGTGAATGCAATATGAAAGAGAGAGCTCTGTGACATCAATCAAGGTTACATTAAT 365

QY 425 TATCTCTCAATTTGGGCGCTTCTACTCTGTGATGATGATATCTTACTCTGTTGAGGCC 484

```

```

366 TATCTCTCTATTTTGGGCGCTTCTGCTTCTGTATCATGTTATCTTACCTTAGTTGAGGCC 425
485 ATACTGAAGAGCGGCTCTTTGGACATGCACAGTTGATACAGAGTGATGATGATATGGG 544
426 ATCTTGAAGAGCGGCTCTTTGGACACTCCAGCTGTTTGCAGAGCGATGATGACGTTGG 485
545 GATCACCAGCGCTTTTCAAAATGCACAGATGTGCTAGCCCGCTCCCGCAGTGCAGCAAC 604
486 GATCACCAGCGCTTTTCAAAATGCCATGATGTGTGGCCCGCTCTCGCAGCGAGCAAT 545
605 GTCTGAAACAGGTAGAAATATGCACAGAGCGCTGGAAGCTTCAAGTCCAAAGAGCGCA 664
546 GTTCTAAACAGGTGGAGTACGCTCAGCAGCGCTGGAAGCTCAGGTCCAGAGAGCGCA 605
665 AAGTCTGTCTTTGACCGCGATGTTGCTCCTCAGCTAATTTGGGAATTTGAAATTCAGGTGACT 724
606 AAGTCTGTCTTCGACCGCAGCAGGTTGCTCCTCAGCTAATCTGGAATCTGGAATC-AGGTGACT 664
725 AGAAAGAACAGGACAGCACTGGAAGAACTGACGTGGGTTTTGCTGGGTTTCAAT--T 781
665 AGGAAG-AAACGACAGCACTGGGAAGAAATTTGCTGGGTGTCGCGTCTTAAATGCCA 723
782 TAATACCTTGTGATTTTCACTCACTGTTGCTGGAAGATTTCAAACTGGAAGCAAAACTT 841
724 TGTGTTTTTACAAATCCTTCTGCTGGAAGAGACTCCAACTGGAAGC--AAACCC 781
842 GCTTGATTTTTTTTCTGTTAACTGTAATTAATAGAGACATTTTAAAGACACACAGCTCA 901
782 CATGCTTGGTATTTTCTCTGTTAATATTAATAGAGACATTTTACA-GCACACAGTTCC 840
902 AAGTCAGCCCAATAAGTCTTTTCTCTATTTGCTGATCTTTTACTTAATAAAATAAACTCGCTG 961
841 AAGTCACACAGTAAAGTCTTTTCTCTGTTGATCTTTTACTTAAT-AAATTAAGTCTGCTG 899
962 TAAATATCTTGAAGTCTTTTAACTGGAACAAAGCACTCTCTTTTCCACACATAGTTTAA 1021
900 TGAGTTATCTTGAAGCGCCGCTGCTGGAACAAAGCTCTCTCTTCTTCTGCAACACAGTTCTA 959
1022 ACTTGACTTTCAAGATAATTTTCAAGGTTTTTGTGTTGTTGTTGTTGTTGTTGTTGTTT 1081
960 ACTTGTTTCAAGATAAATTCAGGTGTTTGTGTTGTTGTTGTTGTTGTTGTTGTTGTTT 1011
1082 TGTGAGGAGAGGGGAGGAGTGCCTGGGAAGTGGTTAACTTTTAACTTTTCAAGTCACTTTAC 1141
1012 TGGGAGAGAGAGGAGGAGTGCCTTGGAGTGCCTTGAAGTGA-AGTCTCAAGTCTCTTTTC 1070
1142 TAAACAAATTTTGTAAATAGACCTTACCTTCTATTTTTCGAGTTTCATTTATATTTTGA 1201
1071 CAGACAGACTTATG--AATCTTCAGACCGCTCTACTTCA---CTTGTAAATGTCCTCA 1124
1202 GTGTAGCCAGCCCTCATCAAGAGCTGACTTACTTCAATTTGACTTTTGCAGTCTGACTGATTA 1261
1125 GTGTAG-CTGGCTTGTGAGCGTGTGGCTCCCACTTGCATTTTGCAGTCTGACTACATTA 1183
1262 TCTGGGTATCTG-----CTGTGCTGCACTTCATGTTAAACGGGATCTAAATGCTGTG 1315
1184 CCTAAGATTCTGTGTTAGCCTGTGGCTGCAATTTTATGACAGTGGATCTGAAATGCTGTG 1243
1316 TGGCTTTTCAAAAAAGCAGATTTTCTCATGTGCTGCTGATGCTGATGCTGATGCAATGCTCCT 1375
1244 GGGCTCTCACAATAATGAAGATTTGTTTATGACACTGTGATGCTGACGCAACATGTTCT 1303
1376 AGAACAACTGGCCATTTGCTAGTTTACTCTTAAAGCTAAACATAGTCTTGGTGTGTG 1435
1304 AGAACAGACTGGCCATCTGTAGTTTATACACTGTATACCTTAAACACAGTCTCAGTGTGTG 1363
1436 GTCTTACTCATCTTCTAGTACCTTTTAAAGGACAAATCTTAAAGGACTTTGGACACTTGAATA 1495
1364 GTCTTCTCATCTCTCT-----AGTAGCTCTAAGGACTTTGAACATTTAGATA 1413
1496 AAGAAATTTTATTTTAAACCAAGCCTCCCTGGATGATAATATATACATTTGTGACG 1555
1414 AAGACATTTTCTCTTAAAGCCCAAGCCTCCCTGGATGATTGACGTAACAAATACTGATCAGC 1473

```


Qy	1267	G T A T C T G C T G T G T C G C A C T T C A T G G T A A A C G G G A T C T A A A A T G C C T G G T G G C T T T T C A C	1326
Dd	422	G T A T C T G C T G T G T C T G C A C C T C A T G G T A A A C G G G A T C T A A A A T G C C T G G T G G C T T T T C A C	363
Qy	1327	A A A A G C A G A T T T T C T C A T G T A C T G T A G T G T C T G A T G C A A T G C A T C C T A G A A C A A A C T G	1388
Dd	362	A A A A G C A G A T Y Y C C C A T G T A C T G T A T G T A T S T C Y G A Y G C A A T G C A C C C T A G A A C A A A C T G	303
Qy	1387	G C C A T T T G C T A G T T T A C T C T A A A G A C T A A A C A T A G T C T T G G T G T G T G T G G C T T T A C T A C A T	1444
Dd	302	C C C A T T T G C T A G T Y A C T C T A A G A C T A A C A T A G T C T T G G T G T G T G T G S T C T T A C T A C A T	243
Qy	1447	C T T C T A G T A C T T T A A G G A C A A A T C C T A A G G A C T T G G A C A C T T G C A A T A A G A A A T T T T A	1500
Dd	242	C T T C T A G T A C T T T A A G G A C A A A T C C T A A G G A C T T G G A C A C T Y G C A A T A A A G A A A T T T T A	183
Qy	1507	T T T T A A A C C C A A G C C T C C C T G G A T T G A T A T A T A T A C A C A T T T G T C A G C A T T T C O G G T C G	1566
Dd	182	T Y T T A A C C C A A G C C T C C C T G G A T T G A T A T A T A T A C A C A T T T G T C A G C A T T T C O G G T C G	123
Qy	1567	T G G T A G A G C A G C T G T T T G A G C T C C A A T A T G T C A G C T T T T G A C T A G G C C T G G G T T G T	1629
Dd	122	T G G T A G A G C A G C T G T T T G A G C C C A A T G T G T C A G C C T T G A A C T A G S G C T G G G T T G T	63
Qy	1627	G G G T G C C T C T C T G A A A G G T C T A A C A T T A T G A T A A C T G G C T T T T T C T T C C T A T G T C	1688
Dd	62	G G G T G C M C C T T C G A A A G G T C T A A C C A T T A T T G G A T A A C T - G C T T T T T C T T C C T A T G T C	4
Qy	1687	C T C	1689
Dd	3	C T C	1
RESULT	11		
LOCUS	BX439642		
DEFINITION	BX439642 Homo sapiens PLACENTA Homo sapiens linear EST 15-MAY-2003		
ACCESSION	5-PRIME, mRNA sequence.		
VERSION	1		
KEYWORDS	EST.		
SOURCE	Homo sapiens (human)		
ORGANISM	Homo sapiens		
REFERENCE	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;		
AUTHORS	Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.		
TITLE	1 (bases 1 to 1201)		
JOURNAL	Li, W.B., Gruber, C., Jesse, J. and Polayes, D.		
COMMENT	Full-length cDNA libraries and normalization Unpublished (2001) Contact: Genoscope Genoscope - Centre National de Sequencage BP 191 91006 EVRY cedex - France Email: seqref@genoscope.cns.fr, Web : www.genoscope.cns.fr Library was constructed by life Technologies, a division of Invitrogen. This sequence belongs to sequence cluster 6173.r Contact : Feng Liang Email : fliang@lifetech.com URL : http://fulllength.invitrogen.com/ Invitrogen Corporation 1600 Paradise Avenue Genoscope sequence ID : CSODE012DG10QP1. Location/Qualifiers 1..1201 /organism="Homo sapiens" /mol_type="mRNA" /db_xref="taxon:9606" /clone="CSODE012YN20" /tissue_type="PLACENTA" /clone_lib="Homo sapiens PLACENTA" /note="Vector: PCMVSPORT 6; 1st strand cDNA was primed with a NotI-cligo(dT) primer. Five prime end enriched, double-strand cDNA was digested with Not I and cloned into the Not I and EcoRV sites of the pCMVSPORT 6 vector. Library was not normalized."		
FEATURES	source		
ORIGIN			

